0001179929-21-000171.txt : 20211028 0001179929-21-000171.hdr.sgml : 20211028 20211028104357 ACCESSION NUMBER: 0001179929-21-000171 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLINA HEALTHCARE, INC. CENTRAL INDEX KEY: 0001179929 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 134204626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31719 FILM NUMBER: 211355823 BUSINESS ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 BUSINESS PHONE: 5624353666 MAIL ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 FORMER COMPANY: FORMER CONFORMED NAME: MOLINA HEALTHCARE INC DATE OF NAME CHANGE: 20020812 10-Q 1 moh-20210930.htm 10-Q moh-20210930
000117992912/312021Q3falseP3Y00011799292021-01-012021-09-30xbrli:shares00011799292021-10-22iso4217:USD00011799292021-07-012021-09-3000011799292020-07-012020-09-3000011799292020-01-012020-09-30iso4217:USDxbrli:shares00011799292021-09-3000011799292020-12-310001179929us-gaap:CommonStockMember2020-12-310001179929us-gaap:AdditionalPaidInCapitalMember2020-12-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001179929us-gaap:RetainedEarningsMember2020-12-310001179929us-gaap:RetainedEarningsMember2021-01-012021-03-3100011799292021-01-012021-03-310001179929us-gaap:CommonStockMember2021-01-012021-03-310001179929us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001179929us-gaap:CommonStockMember2021-03-310001179929us-gaap:AdditionalPaidInCapitalMember2021-03-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001179929us-gaap:RetainedEarningsMember2021-03-3100011799292021-03-310001179929us-gaap:RetainedEarningsMember2021-04-012021-06-3000011799292021-04-012021-06-300001179929us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001179929us-gaap:CommonStockMember2021-06-300001179929us-gaap:AdditionalPaidInCapitalMember2021-06-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001179929us-gaap:RetainedEarningsMember2021-06-3000011799292021-06-300001179929us-gaap:RetainedEarningsMember2021-07-012021-09-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001179929us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001179929us-gaap:CommonStockMember2021-09-300001179929us-gaap:AdditionalPaidInCapitalMember2021-09-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001179929us-gaap:RetainedEarningsMember2021-09-300001179929us-gaap:CommonStockMember2019-12-310001179929us-gaap:AdditionalPaidInCapitalMember2019-12-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001179929us-gaap:RetainedEarningsMember2019-12-3100011799292019-12-310001179929us-gaap:RetainedEarningsMember2020-01-012020-03-3100011799292020-01-012020-03-310001179929us-gaap:CommonStockMember2020-01-012020-03-310001179929us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001179929us-gaap:CommonStockMember2020-03-310001179929us-gaap:AdditionalPaidInCapitalMember2020-03-310001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001179929us-gaap:RetainedEarningsMember2020-03-3100011799292020-03-310001179929us-gaap:RetainedEarningsMember2020-04-012020-06-3000011799292020-04-012020-06-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001179929us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001179929us-gaap:CommonStockMember2020-06-300001179929us-gaap:AdditionalPaidInCapitalMember2020-06-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001179929us-gaap:RetainedEarningsMember2020-06-3000011799292020-06-300001179929us-gaap:RetainedEarningsMember2020-07-012020-09-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001179929us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001179929us-gaap:CommonStockMember2020-09-300001179929us-gaap:AdditionalPaidInCapitalMember2020-09-300001179929us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001179929us-gaap:RetainedEarningsMember2020-09-3000011799292020-09-30moh:member0001179929moh:HealthPlansMember2021-09-30moh:position0001179929moh:HealthPlansMembersrt:MinimumMember2021-01-012021-09-300001179929moh:HealthPlansMembersrt:MaximumMember2021-01-012021-09-300001179929moh:NewYorkAcquisitionMedicaidMemberus-gaap:SubsequentEventMember2021-10-252021-10-250001179929stpr:NYmoh:AgeWellNewYorkMember2021-08-310001179929stpr:NYmoh:AgeWellNewYorkMember2020-01-012020-12-310001179929moh:NewYorkAcquisitionMedicaidMemberus-gaap:SubsequentEventMember2021-10-072021-10-0700011799292021-09-012021-09-300001179929moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMembermoh:HidalgoTarrantAndNortheastServiceAreasMember2020-12-310001179929moh:HidalgoServiceAreaMembermoh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember2020-12-310001179929moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember2020-01-012020-12-310001179929moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember2021-04-222021-04-220001179929moh:GovernmentReceivablesMember2021-09-300001179929moh:GovernmentReceivablesMember2020-12-310001179929moh:PharmacyRebateReceivablesMember2021-09-300001179929moh:PharmacyRebateReceivablesMember2020-12-310001179929moh:HealthInsurerFeeReimbursementReceivablesMember2021-09-300001179929moh:HealthInsurerFeeReimbursementReceivablesMember2020-12-310001179929moh:OtherReceivablesMember2021-09-300001179929moh:OtherReceivablesMember2020-12-310001179929moh:CompleteCareReceivablesMember2021-09-300001179929moh:CompleteCareReceivablesMember2020-12-310001179929moh:COVID19Member2021-07-012021-09-300001179929moh:COVID19Member2021-01-012021-09-300001179929moh:StructuredSecuritiesMember2021-01-012021-09-30xbrli:pure0001179929moh:MagellanCompleteCareMember2020-12-310001179929moh:MagellanCompleteCareMember2020-12-312020-12-310001179929moh:MagellanCompleteCareMember2021-01-012021-09-300001179929us-gaap:CorporateDebtSecuritiesMember2021-09-300001179929us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-09-300001179929us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929us-gaap:CommercialMortgageBackedSecuritiesMember2021-09-300001179929us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2021-09-300001179929us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929us-gaap:USTreasuryNotesSecuritiesMember2021-09-300001179929us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryNotesSecuritiesMember2021-09-300001179929us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929us-gaap:AssetBackedSecuritiesMember2021-09-300001179929us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2021-09-300001179929us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929moh:MunicipalSecuritiesMember2021-09-300001179929moh:MunicipalSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Membermoh:MunicipalSecuritiesMember2021-09-300001179929moh:MunicipalSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929moh:OtherSecuritiesMember2021-09-300001179929moh:OtherSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Membermoh:OtherSecuritiesMember2021-09-300001179929moh:OtherSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929us-gaap:FairValueInputsLevel1Member2021-09-300001179929us-gaap:FairValueInputsLevel2Member2021-09-300001179929us-gaap:FairValueInputsLevel3Member2021-09-300001179929moh:PassportHealthPlanIncMemberus-gaap:FairValueInputsLevel3Member2021-09-300001179929us-gaap:CorporateDebtSecuritiesMember2020-12-310001179929us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310001179929us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001179929us-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310001179929us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310001179929us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001179929us-gaap:USTreasuryNotesSecuritiesMember2020-12-310001179929us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001179929us-gaap:USTreasuryNotesSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001179929us-gaap:AssetBackedSecuritiesMember2020-12-310001179929us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2020-12-310001179929us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001179929moh:MunicipalSecuritiesMember2020-12-310001179929moh:MunicipalSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Membermoh:MunicipalSecuritiesMember2020-12-310001179929moh:MunicipalSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001179929us-gaap:FairValueInputsLevel1Member2020-12-310001179929us-gaap:FairValueInputsLevel2Member2020-12-310001179929us-gaap:FairValueInputsLevel3Member2020-12-310001179929moh:PassportHealthPlanIncMember2021-09-300001179929us-gaap:SeniorNotesMembermoh:A4375SeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembermoh:A4375SeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembermoh:A4375SeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembermoh:A4375SeniorNotesMember2020-12-310001179929us-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembermoh:A4375SeniorNotesMember2020-12-310001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Member2021-09-300001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-09-300001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-12-310001179929us-gaap:SeniorNotesMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2021-09-300001179929us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2020-12-310001179929us-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2020-12-310001179929us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300001179929us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-09-300001179929us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001179929us-gaap:EstimateOfFairValueFairValueDisclosureMember2020-12-310001179929moh:MagellanCompleteCareMember2021-09-300001179929moh:MedicaidMember2020-12-310001179929moh:MedicareMember2020-12-310001179929moh:MarketplaceMember2020-12-310001179929moh:MedicaidMember2021-01-012021-09-300001179929moh:MedicareMember2021-01-012021-09-300001179929moh:MarketplaceMember2021-01-012021-09-300001179929moh:MedicaidMember2021-09-300001179929moh:MedicareMember2021-09-300001179929moh:MarketplaceMember2021-09-300001179929moh:MedicaidMember2019-12-310001179929moh:MedicareMember2019-12-310001179929moh:MarketplaceMember2019-12-310001179929moh:MedicaidMember2020-01-012020-09-300001179929moh:MedicareMember2020-01-012020-09-300001179929moh:MarketplaceMember2020-01-012020-09-300001179929moh:MedicaidMember2020-09-300001179929moh:MedicareMember2020-09-300001179929moh:MarketplaceMember2020-09-300001179929us-gaap:SeniorNotesMembermoh:A4375SeniorNotesMember2020-12-310001179929us-gaap:SeniorNotesMembermoh:SeniorNotesDue2022Member2020-12-310001179929us-gaap:SeniorNotesMembermoh:ThreePointEightSevenFivePercentSeniorNotesMember2020-12-310001179929us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-300001179929us-gaap:LineOfCreditMember2021-01-012021-09-300001179929us-gaap:CommonStockMember2021-01-012021-01-310001179929us-gaap:CommonStockMember2021-02-012021-02-280001179929us-gaap:CommonStockMember2021-01-012021-02-280001179929us-gaap:CommonStockMember2020-11-012020-12-310001179929us-gaap:CommonStockMember2020-12-012020-12-310001179929moh:HealthPlansMember2021-07-012021-09-300001179929moh:HealthPlansMember2020-07-012020-09-300001179929moh:HealthPlansMember2021-01-012021-09-300001179929moh:HealthPlansMember2020-01-012020-09-300001179929moh:MedicareMember2021-07-012021-09-300001179929moh:MedicareMember2020-07-012020-09-300001179929moh:MarketplaceMember2021-07-012021-09-300001179929moh:MarketplaceMember2020-07-012020-09-300001179929us-gaap:AllOtherSegmentsMember2021-07-012021-09-300001179929us-gaap:AllOtherSegmentsMember2020-07-012020-09-300001179929us-gaap:AllOtherSegmentsMember2021-01-012021-09-300001179929us-gaap:AllOtherSegmentsMember2020-01-012020-09-300001179929moh:HealthPlansMember2020-12-310001179929us-gaap:AllOtherSegmentsMember2021-09-300001179929us-gaap:AllOtherSegmentsMember2020-12-310001179929moh:HealthPlansMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001179929moh:HealthPlansMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001179929moh:HealthPlansMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001179929moh:HealthPlansMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001179929moh:MedicareMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001179929moh:MedicareMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001179929moh:MedicareMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001179929moh:MedicareMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001179929moh:MarketplaceMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001179929moh:MarketplaceMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001179929moh:MarketplaceMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001179929moh:MarketplaceMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001179929us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001179929us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001179929us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001179929us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001179929us-gaap:OperatingSegmentsMember2021-07-012021-09-300001179929us-gaap:OperatingSegmentsMember2020-07-012020-09-300001179929us-gaap:OperatingSegmentsMember2021-01-012021-09-300001179929us-gaap:OperatingSegmentsMember2020-01-012020-09-300001179929us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300001179929us-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300001179929us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300001179929us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission file number: 001-31719
moh-20210930_g1.jpg
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware 13-4204626
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
200 Oceangate, Suite 100
 
Long Beach,California90802
(Address of principal executive offices) (Zip Code)
(562) 435-3666
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value MOHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer   Accelerated Filer Non-Accelerated Filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No  
The number of shares of the issuer’s Common Stock, $0.001 par value, outstanding as of October 22, 2021, was approximately 58,400,000.


MOLINA HEALTHCARE, INC. FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021

TABLE OF CONTENTS




CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions, except per-share amounts)
(Unaudited)
Revenue:
Premium revenue$6,800 $4,768 $19,689 $13,444 
Premium tax revenue204 170 576 477 
Health insurer fees reimbursed 69  206 
Investment income 20 10 39 48 
Other revenue16 4 58 13 
Total revenue7,040 5,021 20,362 14,188 
Operating expenses:
Medical care costs6,049 4,098 17,342 11,412 
General and administrative expenses532 368 1,489 1,030 
Premium tax expenses204 170 576 477 
Health insurer fees 70  209 
Depreciation and amortization32 23 96 64 
Other2 3 30 9 
Total operating expenses6,819 4,732 19,533 13,201 
Operating income221 289 829 987 
Other expenses, net:
Interest expense30 27 90 72 
Other expense, net   5 
Total other expenses, net30 27 90 77 
Income before income tax expense191 262 739 910 
Income tax expense48 77 183 271 
Net income$143 $185 $556 $639 
Net income per share - Basic $2.49 $3.14 $9.63 $10.80 
Net income per share - Diluted $2.46 $3.10 $9.51 $10.65 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
(Unaudited)
Net income$143 $185 $556 $639 
Other comprehensive loss income:
Unrealized investment (loss) income(13)6 (27)43 
Less: effect of income taxes
(4)1 (7)10 
Other comprehensive (loss) income, net of tax (9)5 (20)33 
Comprehensive income$134 $190 $536 $672 
See accompanying notes.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 3

CONSOLIDATED BALANCE SHEETS
September 30,
2021
December 31,
2020
(Dollars in millions,
except per-share amounts)
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$4,357 $4,154 
Investments2,900 1,875 
Receivables1,912 1,672 
Prepaid expenses and other current assets197 175 
Total current assets9,366 7,876 
Property, equipment, and capitalized software, net385 391 
Goodwill, and intangible assets, net915 941 
Restricted investments156 136 
Deferred income taxes 83 69 
Other assets128 119 
Total assets$11,033 $9,532 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable$3,191 $2,696 
Amounts due government agencies 2,081 1,253 
Accounts payable, accrued liabilities and other797 641 
Deferred revenue1 375 
Total current liabilities6,070 4,965 
Long-term debt2,130 2,127 
Finance lease liabilities220 225 
Other long-term liabilities95 119 
Total liabilities8,515 7,436 
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2021, and 59 million shares at December 31, 2020
  
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
  
Additional paid-in capital205 199 
Accumulated other comprehensive income17 37 
Retained earnings2,296 1,860 
Total stockholders’ equity2,518 2,096 
Total liabilities and stockholders’ equity$11,033 $9,532 
See accompanying notes.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 4

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Common StockAdditional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Retained
Earnings
Total
OutstandingAmount
(In millions)
(Unaudited)
Balance at December 31, 202059 $ $199 $37 $1,860 $2,096 
Net income— — — — 228 228 
Common stock purchases(1)— (2)— (120)(122)
Other comprehensive loss, net— — — (11)— (11)
Share-based compensation— — (27)— — (27)
Balance at March 31, 202158  170 26 1,968 2,164 
Net income— — — — 185 185 
Share-based compensation— — 21 — — 21 
Balance at June 30, 202158  191 26 2,153 2,370 
Net income— — — — 143 143 
Other comprehensive loss, net— — — (9)— (9)
Share-based compensation— — 14 — — 14 
Balance at September 30, 202158 $ $205 $17 $2,296 $2,518 

Common StockAdditional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Retained
Earnings
Total
OutstandingAmount
(In millions)
(Unaudited)
Balance at December 31, 201962 $ $175 $4 $1,781 $1,960 
Net income— — — — 178 178 
Common stock purchases(3)— (9)— (437)(446)
Termination of warrants— — (30)— — (30)
Other comprehensive loss, net— — — (19)— (19)
Share-based compensation— — 4 — — 4 
Balance at March 31, 202059  140 (15)1,522 1,647 
Net income— — — — 276 276 
Other comprehensive income, net— — — 47 — 47 
Share-based compensation— — 26 — — 26 
Balance at June 30, 202059  166 32 1,798 1,996 
Net income— — — — 185 185 
Other comprehensive income, net— — — 5 — 5 
Share-based compensation— — 15 — — 15 
Balance at September 30, 202059 $ $181 $37 $1,983 $2,201 
See accompanying notes.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 5

CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30,
 20212020
(In millions)
(Unaudited)
Operating activities:
Net income$556 $639 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization96 64 
Deferred income taxes(8)(3)
Share-based compensation49 43 
Loss on debt repayment  5 
Other, net9 2 
Changes in operating assets and liabilities:
Receivables(247)(369)
Prepaid expenses and other current assets(43)(98)
Medical claims and benefits payable522 431 
Amounts due government agencies 810 (24)
Accounts payable, accrued liabilities and other129 63 
Deferred revenue(374)(188)
Income taxes23 34 
Net cash provided by operating activities1,522 599 
Investing activities:
Purchases of investments(2,018)(670)
Proceeds from sales and maturities of investments965 891 
Purchases of property, equipment and capitalized software(56)(64)
Net cash paid in business combinations (62)
Other, net3 3 
Net cash (used in) provided by investing activities(1,106)98 
Financing activities:
Common stock purchases(128)(453)
Common stock withheld to settle employee tax obligations(52)(8)
Contingent consideration liabilities settled(20) 
Proceeds from senior notes offering, net of issuance costs  789 
Repayment of term loan facility (600)
Proceeds from borrowings under term loan facility 380 
Other, net(4)(47)
Net cash (used in) provided by financing activities(204)61 
Net increase in cash, cash equivalents, and restricted cash and cash equivalents212 758 
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period4,223 2,508 
Cash, cash equivalents, and restricted cash and cash equivalents at end of period$4,435 $3,266 

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
SEPTEMBER 30, 2021

1. Organization and Basis of Presentation
Organization and Operations
Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. For further information, refer to Note 10, “Segments.”
As of September 30, 2021, we served approximately 4.8 million members eligible for government-sponsored healthcare programs, located across 18 states.
Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFPs”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.
In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (“ABD”); and regions or service areas.
Recent Developments
New York Acquisition—Medicaid. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.
New York Acquisition—Medicaid. On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.
Nevada Procurement—Medicaid. On August 17, 2021, we announced that our Nevada health plan subsidiary was selected as an awardee in Clark and Washoe Counties. This new contract is expected to commence on January 1, 2022, and will offer health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two year extension was ratified in September 2021.
California Procurement—Medicaid. The state currently expects a final RFP to be released in February 2022.
Texas Acquisition—Medicaid and Medicare. On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.
Ohio Procurement—Medicaid. On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin July 1, 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 7

Consolidation and Interim Financial Information
The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results for the entire year ending December 31, 2021.
The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, 2020, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, 2020.
Reclassifications
Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.
Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:
The determination of medical claims and benefits payable;
Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;
Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;
Settlements under risk- or savings-sharing programs;
Purchase price allocations relating to business combinations, including the determination of contingent consideration;
The assessment of long-lived and intangible assets, and goodwill for impairment;
The determination of reserves for potential absorption of claims unpaid by insolvent providers;
The determination of reserves for the outcome of litigation;
The determination of valuation allowances for deferred tax assets; and
The determination of unrecognized tax benefits.

2. Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 8

September 30,
 20212020
(In millions)
Cash and cash equivalents$4,357 $3,196 
Restricted cash and cash equivalents78 70 
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$4,435 $3,266 
Receivables
Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.
September 30,
2021
December 31,
2020
(In millions)
Government receivables$1,331 $969 
Pharmacy rebate receivables264 178 
Health insurer fee reimbursement receivables25 104 
Other292 255 
Magellan Complete Care acquisition opening balance  166 
Total$1,912 $1,672 
Premium Revenue Recognition and Amounts Due Government Agencies
Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.
Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 9

Contractual Provisions That May Adjust or Limit Revenue or Profit
Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:
September 30,
2021
December 31,
2020
(In millions)
Medicaid:
Minimum MLR and profit sharing$852 $513 
Other249 76 
Medicare:
Risk adjustment and Part D risk sharing87 45 
Minimum MLR and profit sharing 82 62 
Other41 30 
Marketplace:
Risk adjustment691 326 
Minimum MLR30 37 
Other49 21 
Magellan Complete Care acquisition opening balance 143 
Total amounts due government agencies$2,081 $1,253 
Medicaid
Minimum MLR and Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable. Our adjustment is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.
Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.
It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Marketplace
Risk Adjustment. Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September 30, 2021, Marketplace risk adjustment payables amounted to $691 million and related receivables amounted to $29 million, for a net payable of $662 million, of which $660 million related to 2021, and $2 million related primarily to 2020. As of December 31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306 million.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 10

Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.
Income Taxes
The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.
The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.
Recent Accounting Pronouncements
Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

3. Net Income per Share
The following table sets forth the calculation of net income per share:
Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
 (In millions, except net income per share)
Numerator:
Net income$143 $185 $556 $639 
Denominator:
Shares outstanding at the beginning of the period57.8 58.7 58.0 61.9 
Weighted-average number of shares issued:
Stock purchases  (0.5)(2.8)
Stock-based compensation  0.3 0.1 
Denominator for basic net income per share57.8 58.7 57.8 59.2 
Effect of dilutive securities: (1)
Stock-based compensation0.7 0.9 0.7 0.8 
Denominator for diluted net income per share58.5 59.6 58.5 60.0 
Net income per share - Basic (2)
$2.49 $3.14 $9.63 $10.80 
Net income per share - Diluted (2)
$2.46 $3.10 $9.51 $10.65 
______________________________
(1)    The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.
(2)    Source data for calculations in thousands.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 11

    
4. Business Combinations
On December 31, 2020, we closed on our acquisition of 100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $1,037 million. In the nine months ended September 30, 2021, we recorded various measurement period adjustments, including a decrease of $7 million to “Receivables,” a decrease of $27 million to “Medical claims and benefits payable,” and an increase of $18 million to “Amounts due government agencies.” In the aggregate, we recorded a net increase of $9 million to goodwill for these measurement period adjustments and various purchase price adjustments.
Refer to Note 10, “Segments” for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.

5. Fair Value Measurements
We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, “Fair Value Measurements.”
Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1) (Level 2) (Level 3)
 (In millions)
Corporate debt securities$1,705 $ $1,705 $ 
Mortgage-backed securities610  610  
U.S. Treasury notes235  235  
Asset-backed securities224  224  
Municipal securities97  97  
Other
29  29  
Total assets$2,900 $ $2,900 $ 
Contingent consideration liabilities$26 $ $ $26 
Total liabilities$26 $ $ $26 
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 12

Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1)(Level 2)(Level 3)
 (In millions)
Corporate debt securities$1,256 $ $1,256 $ 
Mortgage-backed securities392  392  
U.S. Treasury notes27  27  
Asset-backed securities132  132  
Municipal securities68  68  
Total assets $1,875 $ $1,875 $ 
Contingent consideration liabilities $46 $ $ $46 
Total liabilities$46 $ $ $46 
The net changes in fair value of Level 3 financial instruments are reported in “Other” operating expenses in our consolidated statements of income. In the nine months ended September 30, 2021, we recognized a loss of $3 million for the increase in the fair value of the contingent consideration liabilities described below.
Contingent Consideration Liabilities
As of September 30, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $26 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23 million, was paid to the seller. The portion of the contingent purchase consideration paid in the first quarter of 2021 has been presented primarily in “Financing activities” in the accompanying consolidated statements of cash flows for the nine months ended September 30, 2021, with the balance reflected in “Operating activities.” We expect to pay the remaining balance of the liabilities, reported in “Accounts payable, accrued liabilities and other” in the accompanying consolidated balance sheets, by the end of the first quarter of 2022.
Fair Value Measurements – Disclosure Only
The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.
 September 30, 2021December 31, 2020
 Carrying
Amount
Fair Value Carrying
Amount
Fair Value
 (In millions)
4.375% Notes
$790 $835 $789 $843 
5.375% Notes
698 725 697 742 
3.875% Notes
642 688 641 691 
Total$2,130 $2,248 $2,127 $2,276 

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 13

6. Investments
Available-for-Sale
We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:
 September 30, 2021
Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,688 $19 $2 $1,705 
Mortgage-backed securities607 4 1 610 
U.S. Treasury notes
235   235 
Asset-backed securities223 1  224 
Municipal securities96 1  97 
Other29   29 
Total$2,878 $25 $3 $2,900 

 December 31, 2020
 Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,220 $36 $ $1,256 
Mortgage-backed securities383 10 1 392 
U.S. Treasury notes
27   27 
Asset-backed securities130 2  132 
Municipal securities66 2  68 
Total$1,826 $50 $1 $1,875 
The contractual maturities of our available-for-sale investments as of September 30, 2021 are summarized below:
Amortized CostEstimated
Fair Value
 (In millions)
Due in one year or less$555 $557 
Due after one year through five years1,530 1,546 
Due after five years through ten years296 298 
Due after ten years497 499 
Total$2,878 $2,900 
Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to $6 million and $7 million for the three and nine months ended September 30, 2021, respectively. Gross realized investment gains were insignificant for three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2021, and 2020.
We have determined that unrealized losses at September 30, 2021, and December 31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 14

The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of September 30, 2021, and December 31, 2020.
 September 30, 2021December 31, 2020
 Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
 (Dollars in millions)
Corporate debt securities$509 $2 174 $ $  
Mortgage-backed securities
270 1 94 77 1 21 
Total$779 $3 268 $77 $1 21 

Held-to-Maturity
Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.
We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $156 million at September 30, 2021, of which $148 million will mature in one year or less, and $8 million will mature after one through five years.

7. Medical Claims and Benefits Payable
The following table provides the details of our medical claims and benefits payable as of the dates indicated:
September 30,
2021
December 31,
2020
 (In millions)
Fee-for-service claims incurred but not paid (“IBNP”)$2,246 $1,647 
Pharmacy payable209 157 
Capitation payable86 70 
Other650 528 
Magellan Complete Care acquisition opening balance 294 
Total$3,191 $2,696 
“Other” medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $301 million and $235 million as of September 30, 2021, and December 31, 2020, respectively.
The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for “Components of medical care costs related to: Prior years” represent decreases in medical care costs resulting from actual medical care costs being less than we previously estimated in the prior year.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 15

Nine Months Ended September 30, 2021
Medicaid Medicare MarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$2,129 $392 $175 $2,696 
Components of medical care costs related to:
Current year13,491 2,195 1,872 17,558 
Prior years(158)(36)(22)(216)
Total medical care costs13,333 2,159 1,850 17,342 
Payments for medical care costs related to:
Current year11,530 1,816 1,534 14,880 
Prior years1,538 340 130 2,008 
Total paid13,068 2,156 1,664 16,888 
Change in acquired balances (19)(8) (27)
Change in non-risk and other provider payables68   68 
Medical claims and benefits payable, ending balance$2,443 $387 $361 $3,191 

Nine Months Ended September 30, 2020
Medicaid MedicareMarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$1,465 $267 $122 $1,854 
Components of medical care costs related to:
Current year9,029 1,588 861 11,478 
Prior years(41)(25) (66)
Total medical care costs8,988 1,563 861 11,412 
Payments for medical care costs related to:
Current year7,470 1,316 714 9,500 
Prior years1,193 233 101 1,527 
Total paid8,663 1,549 815 11,027 
Change in non-risk and other provider payables50   50 
Medical claims and benefits payable, ending balance$1,840 $281 $168 $2,289 
Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $216 million and $66 million as of September 30, 2021, and 2020, respectively.
The favorable prior period development recognized in the nine months ended September 30, 2021 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our previous estimates in 2020.

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 16

8. Debt
All long-term debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:
September 30,
2021
December 31,
2020
(In millions)
Non-current long-term debt:
4.375% Notes due 2028
$800 $800 
5.375% Notes due 2022
700 700 
3.875% Notes due 2030
650 650 
Deferred debt issuance costs (20)(23)
Total$2,130 $2,127 
Credit Agreement
We are party to a credit agreement (“Credit Agreement”) which includes a revolving credit facility (“Credit Facility”) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.
The Credit Agreement contains customary non-financial and financial covenants. As of September 30, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September 30, 2021, no amounts were outstanding under the Credit Facility.
High-Yield Senior Notes
Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contains customary non-financial covenants and change of control provisions.
The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.
4.375% Notes due 2028. We had $800 million aggregate principal amount of senior notes (the “4.375% Notes”) outstanding as of September 30, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.
5.375% Notes due 2022. We had $700 million aggregate principal amount of senior notes (the “5.375% Notes”) outstanding as of September 30, 2021, which are due November 15, 2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15.
3.875% Notes due 2030. We had $650 million aggregate principal amount of senior notes (the “3.875% Notes”) outstanding as of September 30, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.

9. Stockholders' Equity
In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program immediately supersedes the stock purchase program previously approved by our board of directors in September 2020. This new program will be funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of October 28, 2021, no shares had been purchased under the stock purchase program approved in 2021.
In September 2020, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 17

plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In November and December 2020, we purchased 766,000 shares of our common stock for $159 million (average cost of $208.37), including approximately 29,000 shares purchased for $6 million in late December 2020, and settled in early January 2021.

10. Segments
In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.
The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.
The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (“MCR”). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.
For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.
The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Total revenue:
Medicaid$5,354 $3,996 $15,583 $11,124 
Medicare875 636 2,502 1,909 
Marketplace793 389 2,224 1,155 
Other18  53  
Total$7,040 $5,021 $20,362 $14,188 
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 18

The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.
September 30,December 31,
20212020
(In millions)
Goodwill:
Medicaid$387 $378 
Medicare247 247 
Other67 67 
Intangibles assets, net:
Medicaid135 157 
Medicare65 76 
Other14 16 
Total$915 $941 
The following table reconciles margin by segment to consolidated income before income taxes.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Margin:
Medicaid$532 $509 $1,687 $1,427 
Medicare151 91 329 333 
Marketplace68 70 331 272 
Other 4  11  
Total margin 755 670 2,358 2,032 
Add: other operating revenues (1)
222 253 620 744 
Less: other operating expenses (2)
(756)(634)(2,149)(1,789)
Operating income221 289 829 987 
Other expenses, net30 27 90 77 
Income before income tax expense$191 $262 $739 $910 
______________________
(1)Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.
(2)Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.
11. Commitments and Contingencies
COVID-19 Pandemic
We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 19

Legal Proceedings
The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. The consequences associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.
We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Kentucky RFP. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the Court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare of Kentucky and Anthem. The new Medicaid contracts commenced on January 1, 2021. On April 28, 2021, the Court issued its preliminary Opinion and Order, which Opinion and Order the Court finalized on June 16, 2021. Under the final Order, which the Court indicated is immediately appealable by the parties, the Court, among other things, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina’s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the Court ordered a new RFP, with the status quo of six health plans serving Kentucky Medicaid members to continue in the interim. On July 15-16, 2021, each of United, Molina, Humana, and Aetna filed notices of appeal. On July 23, 2021, both the Kentucky Finance and Administration Cabinet and the Kentucky Cabinet for Health and Family Services filed notices of cross appeal, and on July 26, 2021, Anthem filed a notice of cross appeal. This matter remains subject to potential additional legal and appellate proceedings, and no assurances can be given regarding the ultimate outcome. Under the Court’s June 16, 2021 final Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.
Puerto Rico. On August 13, 2021, Molina Healthcare of Puerto, Inc. (MHPR) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (ASES). On September 13, 2021, in addition to filing its answer to MHPR’s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers and, in addition to damages, seeks various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations. This matter is in its early stages, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR’s complaint or the counterclaim of ASES.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 20

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (“MD&A”)
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section 27A of the Securities Act of 1933, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “guidance,” “future,” “anticipates,” “believes,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled “Risk Factors” in our 2020 Annual Report on Form 10-K, including without limitation the following:
the impact of the COVID-19 pandemic and its associated or indirect effects on our business, operations, and financial results, including without limitation the duration of the Public Health Emergency Declaration (“PHE”) and associated suspension in redeterminations, and the potential impact on our workforce or contractors of federal or state vaccine mandates;
significant budget pressures on state governments from diminished tax revenues incidental to the COVID-19 pandemic and their efforts to reduce rates or limit rate increases, to impose profit caps or risk corridors, or to recoup previously paid premium amounts on a retroactive basis;
the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the “ACA”);
the market dynamics surrounding the ACA Marketplaces, including issues impacting enrollment, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;
the outcome of the legal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan and our acquisition of certain assets of Passport;
the success of our efforts to retain existing or awarded government contracts, and the success of any bid submissions in response to requests for proposal, including our contracts in California and Texas;
subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment;
our ability to consummate, integrate, and realize benefits from acquisitions, including the completed acquisitions of Magellan Complete Care, Passport, and Affinity, and the announced acquisitions of AgeWell New York and the Medicaid assets of Cigna in Texas;
effective management of our medical costs;
our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19;
cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected information;
the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives;
our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs;
our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs;
the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements;
our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements;
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 21

the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members;
the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith;
the success and renewal of our Medicare-Medicaid Plan (“MMP”) programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas;
the accurate estimation of incurred but not reported or paid medical costs across our health plans;
efforts by states to recoup previously paid and recognized premium amounts;
changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;
complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;
fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;
our exit from Puerto Rico, including the payment in full of our outstanding accounts receivable, the effective run-out of claims, the return of our capital, and the outcome of the claims filed against our Puerto Rico health plan and us by the Puerto Rico Health Insurance Administration, or ASES;
changes with respect to our provider contracts and the loss of providers;
approval by state regulators of dividends and distributions by our health plan subsidiaries;
changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;
high dollar claims related to catastrophic illness;
the resolution, favorable or unfavorable, of litigation, arbitration, or administrative proceedings;
the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;
the failure to comply with the financial or other covenants in the Credit Agreement or the indentures governing our outstanding notes;
the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;
the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;
the failure of a state in which we operate to renew its federal Medicaid waiver;
changes generally affecting the managed care industry;
increases in government surcharges, taxes, and assessments;
the unexpected loss of the leadership of one or more of our senior executives; and
increasing competition and consolidation in the Medicaid industry.
Each of the terms “Molina Healthcare, Inc.” “Molina Healthcare,” “Company,” “we,” “our,” and “us,” as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.
Readers should refer to the section entitled “Risk Factors” in our 2020 Annual Report on Form 10-K, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.
This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management’s Discussion and Analysis appearing in our 2020 Annual Report on Form 10-K.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 22

OVERVIEW
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). We served approximately 4.8 million members as of September 30, 2021.
THIRD QUARTER 2021 HIGHLIGHTS
We reported net income of $143 million, or $2.46 per diluted share, for the third quarter of 2021, which reflected the following:
Membership increase of 0.8 million, or 20%, compared with September 30, 2020, and a 142,000 sequential increase compared to June 30, 2021;
Premium revenue of $6.8 billion, which increased 43% compared with the third quarter of 2020, reflecting increased organic membership in all lines of business, along with the impact of acquisitions;
Consolidated medical care ratio (“MCR”) was 88.9%, compared with 85.9% for the third quarter of 2020, and increased due to the net effect of COVID, which increased the MCR by 110 basis points in the third quarter of 2021, but was slightly positive in the third quarter of 2020;
General and administrative expense (“G&A”) ratio of 7.5%, which increased compared with 7.3% in the third quarter of 2020, reflecting appropriate investments to support our business growth and increased acquisition-related expenses, partially offset by the benefits of revenue growth and continued discipline in cost management; and
After-tax margin of 2.0%, which met our expectations.
We note the following factors impacting the 2021 third quarter financial results:
We estimate that the net effect of COVID decreased net income by approximately $1.00 per diluted share in the third quarter of 2021. The net effect of COVID was slightly positive in the third quarter of 2020.
The net effect of COVID reflects higher COVID inpatient costs, lower COVID-related utilization curtailment and the impact of the COVID risk-sharing corridors, and impacted all our segments.
We experienced higher than expected membership increases in Marketplace. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, and the extended open enrollment period, as described in further detail below in “Trends and Uncertainties.”

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 23

CONSOLIDATED FINANCIAL SUMMARY
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
 (In millions, except per-share amounts)
Premium revenue$6,800 $4,768 $19,689 $13,444 
Less: medical care costs6,049 4,098 17,342 11,412 
Medical margin751 670 2,347 2,032 
MCR (1)
88.9 %85.9 %88.1 %84.9 %
Other revenues:
Premium tax revenue204 170 576 477 
Health insurer fees reimbursed— 69 — 206 
Investment income20 10 39 48 
Other revenue16 58 13 
General and administrative expenses532 368 1,489 1,030 
G&A ratio (2)
7.5 %7.3 %7.3 %7.3 %
Premium tax expenses204 170 576 477 
Health insurer fees— 70 — 209 
Depreciation and amortization32 23 96 64 
Other30 
Operating income221 289 829 987 
Interest expense30 27 90 72 
Other expense, net— — — 
Income before income tax expense191 262 739 910 
Income tax expense48 77 183 271 
Net income$143 $185 $556 $639 
Net income per share – Diluted
$2.46 $3.10 $9.51 $10.65 
Diluted weighted average shares outstanding58.5 59.6 58.5 60.0 
Other Key Statistics
Ending membership4.8 4.0 4.8 4.0 
Effective income tax rate24.8 %29.5 %24.7 %29.8 %
After-tax margin (3)
2.0 %3.7 %2.7 %4.5 %
________________________
(1)    MCR represents medical care costs as a percentage of premium revenue.
(2)    G&A ratio represents general and administrative expenses as a percentage of total revenue.
(3)    After-tax margin represents net income as a percentage of total revenue.

CONSOLIDATED RESULTS
NET INCOME AND OPERATING INCOME
Net income in the third quarter of 2021 amounted to $143 million, or $2.46 per diluted share, compared with $185 million, or $3.10 per diluted share, in the third quarter of 2020. We estimate that the net effect of COVID decreased net income by approximately $1.00 per diluted share in the third quarter of 2021. In the third quarter of 2020, the net effect of COVID had a slightly positive impact on earnings.
Operating income of $221 million in the third quarter of 2021, was lower compared with $289 million in the third quarter of 2020.
Net income in the nine months ended September 30, 2021 amounted to $556 million, or $9.51 per diluted share, compared with $639 million, or $10.65 per diluted share, in the nine months ended September 30, 2020. Operating
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 24

income of $829 million in the nine months ended September 30, 2021, was lower compared with $987 million in the nine months ended September 30, 2020.
The decrease in operating income for both periods was mainly due to the increase in MCR, due primarily to the net effect of COVID, partially offset by membership growth and higher premium revenues.
The year-over-year comparison between 2020 and 2021 is significantly impacted by the positive net effect of COVID that characterized the relatively early phases of the pandemic in the second and third quarters of 2020.
Net income per share in the third quarter and nine months ended September 30, 2021 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchases in late 2020 and early 2021. See further discussion in “Liquidity and Financial Condition,” below.
PREMIUM REVENUE
Premium revenue increased $2.0 billion, or 43%, in the third quarter of 2021, when compared with the third quarter of 2020, and increased $6.2 billion, or 46%, in the nine months ended September 30, 2021, when compared with the nine months ended September 30, 2020.
Membership increased by 805,000 compared with September 30, 2020, which mainly reflected organic increases in the Medicaid and Marketplace segments and the impact from the Magellan Complete Care and other acquisitions that closed in the second half of 2020. The increase in premium revenue was net of COVID-related risk corridors that have been enacted in several states beginning in the second quarter of 2020.
MEDICAL CARE RATIO
The consolidated MCR in the third quarter of 2021 was 88.9%, compared with 85.9% in the third quarter of 2020. The net effect of COVID increased the consolidated MCR by approximately 110 basis points in the third quarter of 2021, and reflects higher COVID inpatient costs, lower COVID-related utilization curtailment and the impact of the risk-sharing corridors, and impacted all our segments. In the prior year the net effect of COVID had a slightly favorable impact to the consolidated MCR.
The consolidated MCR in the nine months ended September 30, 2021 was 88.1%, compared with 84.9% in the nine months ended September 30, 2020. Similar to the quarter-to-date consolidated MCR, the increase is due to the net effect of COVID; however, the impacts were varied by segment.
The prior year reserve development in the third quarter and nine months ended September 30, 2021 was modestly favorable, but its impact on earnings was mostly absorbed by the COVID-related risk corridors.
PREMIUM TAX REVENUE AND EXPENSES
The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was 2.9% and 3.4% for the third quarter of 2021 and 2020, respectively, and 2.8% and 3.4% for the nine months ended September 30, 2021 and 2020, respectively. The current year ratio decrease was mainly due to changes in business mix resulting from the Magellan Complete Care and other acquisitions closed in the second half of 2020.
INVESTMENT INCOME
Investment income increased to $20 million in the third quarter of 2021, compared with $10 million in the third quarter of 2020, due to higher invested assets and increased realized gains. Investment income decreased to $39 million in the nine months ended September 30, 2021, compared with $48 million in the nine months ended September 30, 2020. The year-over-year decrease was due to the continued low interest rate environment and a temporarily higher allocation in shorter-term invested assets during the COVID-19 pandemic, which was rescinded effective for the second quarter of 2021.
OTHER REVENUE
Other revenue increased to $16 million in the third quarter of 2021, compared with $4 million in the third quarter of 2020, and increased to $58 million in the nine months ended September 30, 2021, compared with $13 million in the nine months ended September 30, 2020. Beginning in the first quarter of 2021, other revenue includes service revenue associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of our Magellan Complete Care acquisition.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 25

G&A EXPENSES
The G&A expense ratio increased to 7.5% in the third quarter of 2021, compared with 7.3% in the third quarter of 2020. The G&A expense ratio was 7.3% in the nine months ended September 30, 2021, consistent with the nine months ended September 30, 2020. The year over year comparisons for both periods are impacted by appropriate investments to support our business growth and increased acquisition-related expenses, partially offset by continued discipline in cost management and increased revenues.
HEALTH INSURER FEES (“HIF”)
There were no HIF fees incurred or reimbursed in 2021, because the HIF was repealed effective for years after 2020.
DEPRECIATION AND AMORTIZATION
Depreciation and amortization increased to $32 million in the third quarter of 2021, compared with $23 million in the third quarter of 2020, and increased to $96 million in the nine months ended September 30, 2021, compared with $64 million in the nine months ended September 30, 2020. The increases in both periods were due primarily to amortization associated with acquisitions completed in the second half of 2020.
Refer to Notes to Consolidated Financial Statements, Note 10, “Segments,” for further information.
OTHER OPERATING EXPENSES
Other operating expenses decreased to $2 million in the third quarter of 2021, compared with $3 million in the third quarter of 2020, and increased to $30 million in the nine months ended September 30, 2021, compared with $9 million in the nine months ended September 30, 2020. Beginning in the first quarter of 2021, other operating expenses include service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as noted above.
INTEREST EXPENSE
Interest expense increased to $30 million in the third quarter of 2021, compared with $27 million in the third quarter of 2020, and to $90 million in the nine months ended September 30, 2021, compared with $72 million in the nine months ended September 30, 2020, mainly due to the $650 million principal amount of 3.875% Notes issued in the fourth quarter of 2020.
See further details of our financing transactions in Notes to Consolidated Financial Statements, Note 8, “Debt,” and below in “Liquidity and Financial Condition.”
INCOME TAXES
Income tax expense amounted to $48 million in the third quarter of 2021, or 24.8% of pretax income, compared with income tax expense of $77 million, or 29.5% of pretax income in the third quarter of 2020. Income tax expense amounted to $183 million in the nine months ended September 30, 2021, or 24.7% of pretax income, compared with income tax expense of $271 million, or 29.8% of pretax income in the nine months ended September 30, 2020. The effective tax rate is lower in 2021 mainly because the nondeductible HIF was repealed for years after 2020.

TRENDS AND UNCERTAINTIES
COVID-19 PANDEMIC
As the COVID-19 pandemic continues to evolve, its ongoing impact to our business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Medicaid, Medicare, and Marketplace segments follow.
Federal Economic Stabilization and Other Programs
In addition to various programs enacted in 2020 and described in our 2020 Annual Report on Form 10-K, the $1.9 trillion American Rescue Plan Act of 2021 was enacted on March 11, 2021. This legislation includes several components to assist in COVID-19 vaccine testing and deployment, as well as provisions relating to the opening of schools; direct immediate relief to working families; and additional support for communities struggling in the wake of the pandemic. Among its specific provisions:
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 26

$350 billion in state and local funding;
Funding for Medicaid and CHIP COVID-19 vaccines and treatment to be matched at 100% of the federal medical assistance percentage (“FMAP”);
Incentives for states that have not expanded Medicaid to do so;
State flexibility to extend Medicaid eligibility to women for 12 months postpartum;
A temporary 10% FMAP increase for states to improve Medicaid home- and community-based services for one year; and
An increase to the ACA Marketplace premium subsidies for 2021 and 2022.
In addition, the Biden Administration has extended the COVID-19 related PHE. The Biden Administration has indicated the PHE will likely remain in place throughout 2021, and that states will receive 60 days’ notice before the end of the PHE to prepare for the end of emergency authorities and the resumption of pre-PHE rules. This extension of the PHE will continue the suspension in state Medicaid eligibility redeterminations.
Also, President Biden’s January 2021 executive order providing for a three-month Marketplace special enrollment period from February 15, 2021 to May 15, 2021, was extended through August 15, 2021. This SEP has now ended in all of our states except for California, where the state-run exchange intends to keep it in place for the remainder of the 2021 benefit year, which ends on December 31, 2021.
Due to the uncertainty as to the duration and breadth of the pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization and other programs to our business, financial condition, and operating results.
Operations
Enrollment and Premium Revenue
Excluding acquisitions and our exit from Puerto Rico, we have added over 700,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-January 2022.
Marketplace revenue growth is now expected to be over 90% in 2021, and we expect to end 2021 with approximately 680,000 members.
The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. In the third quarter and the nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19.
It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Medical Care Costs
We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the potential resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment experienced in the nine months ended September 30, 2021 is likely the result of service deferrals, and so these services will likely be provided to members over the remainder of the year.
Capital and Financial Resources
We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future. Refer to “Liquidity and Financial Condition” below for further discussion of our capital and financial resources.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 27

AFFORDABLE CARE ACT
In December 2018, in a case brought by the state of Texas and nineteen other states, a federal judge in Texas held that the individual mandate of the ACA is unconstitutional. He further held that since the individual mandate is inseverable from the entire body of the ACA, the entire ACA is unconstitutional. The effect of his ruling was stayed pending the appeal of the ruling to the Fifth Circuit Court of Appeals. In December 2019, a three-judge panel of the Fifth Circuit Court of Appeal, in a two to one decision, affirmed the District Court’s ruling that the individual mandate is unconstitutional, but remanded the case back to the District Court for further consideration of the severability issue. The intervenor defendant states led by California subsequently appealed the case to the U.S. Supreme Court, which heard oral arguments in the case on November 10, 2020. In June 2021, the Supreme Court held in a 7-2 opinion that the states and individuals that brought the lawsuit challenging the ACA’s individual mandate did not have standing to challenge the law. Although the Supreme Court did not reach the merits of the challenge, it vacated the District Court’s judgment and remanded the case with instructions to dismiss—effectively ending the case.
OTHER RECENT DEVELOPMENTS
New York Acquisition—Medicaid. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.
New York Acquisition—Medicaid. On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.
Nevada Procurement—Medicaid. On August 17, 2021, we announced that our Nevada health plan subsidiary was selected as an awardee in Clark and Washoe Counties. This new contract is expected to commence on January 1, 2022, and will offer health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two year extension was ratified in September 2021.
California Procurement—Medicaid. The state currently expects a final RFP to be released in February 2022.
Texas Acquisition—Medicaid and Medicare. On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.
Ohio Procurement—Medicaid. On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin July 1, 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs.
For a discussion of additional segment trends, uncertainties and other developments, refer to our 2020 Annual Report on Form 10-K, “Item 1. Business—Our Business,” and “—Legislative and Political Environment.”

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 28

REPORTABLE SEGMENTS
As of September 30, 2021, we served approximately 4.8 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.
In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.
The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.
HOW WE ASSESS PERFORMANCE
We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.
The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (“MCR”). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue.
Management’s discussion and analysis of the change in medical margin is discussed below under “Segment Financial Performance.” For more information, see Notes to Consolidated Financial Statements, Note 10, “Segments.”
SEGMENT MEMBERSHIP
The following table sets forth our membership by segment as of the dates indicated:
September 30,December 31,September 30,
2021 (1)
2020
2020
Medicaid3,981,000 3,599,000 3,595,000 
Medicare138,000 115,000 113,000 
Marketplace719,000 318,000 325,000 
Total4,838,000 4,032,000 4,033,000 
____________________
(1)Approximately 200,000 members, from the Magellan Complete Care acquisition that closed on December 31, 2020, are included in the totals as of September 30, 2021, but not in prior periods.

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 29

SEGMENT FINANCIAL PERFORMANCE
The following tables summarize premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):
Three Months Ended September 30,
20212020
Premium
Revenue
Medical
Margin
MCRPremium
Revenue
Medical
Margin
MCR
Medicaid$5,146 $532 89.6 %$3,754 $509 86.4 %
Medicare875 151 82.8 632 91 85.6 
Marketplace779 68 91.3 382 70 81.6 
Total$6,800 $751 88.9 %$4,768 $670 85.9 %
Nine Months Ended September 30,
20212020
Premium
Revenue
Medical
Margin
MCRPremium
Revenue
Medical
Margin
MCR
Medicaid$15,020 $1,687 88.8 %$10,415 $1,427 86.3 %
Medicare2,488 329 86.8 1,896 333 82.4 
Marketplace2,181 331 84.8 1,133 272 76.0 
Total$19,689 $2,347 88.1 %$13,444 $2,032 84.9 %
Medicaid
Medicaid premium revenue increased $1,392 million in the third quarter of 2021, when compared with the third quarter of 2020. Medicaid premium revenue increased $4,605 million in the nine months ended September 30, 2021, when compared with the nine months ended September 30, 2020. The increase in both periods was mainly due to membership growth and the impact from the Magellan Complete Care and other acquisitions closed in the second half of 2020. Excluding the acquisitions, the membership growth was across several states and was mainly driven by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19. The overall increase was partially offset by the impact of state risk corridors stemming from COVID-19.
As described above in “Trends and Uncertainties,” we recognized approximately $17 million and $183 million in the third quarter and nine months ended September 30, 2021, respectively, for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19.
The medical margin in our Medicaid program increased $23 million in the third quarter of 2021 when compared with the third quarter of 2020. The increase in margin was driven by increased premium revenues, partially offset by the MCR increase discussed below. The medical margin in our Medicaid program increased $260 million in the nine months ended September 30, 2021 when compared with the nine months ended September 30, 2020. The increase was driven by increased premium revenues and margin associated with the membership growth discussed above, partially offset by the MCR increase discussed below.
The Medicaid MCR increased to 89.6% in the third quarter of 2021, from 86.4% in the third quarter of 2020, and increased to 88.8% in the nine months ended September 30, 2021, from 86.3% in the nine months ended September 30, 2020. The increase for both periods is mainly driven by the net effect of COVID and changes in business mix. The net effect of COVID increased the MCR for the current year and reflects an increase in COVID-related inpatient costs, lower COVID-related utilization curtailment and the impact of the COVID-related risk corridors enacted in several states as previously disclosed. In the prior year the net effect of COVID decreased the MCR.
Medicare
Medicare premium revenue increased $243 million in the third quarter of 2021 compared to the third quarter of 2020 and increased $592 million in the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to the impact of the Magellan Complete Care acquisition, including higher membership and higher premium revenue PMPM.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 30

The medical margin for Medicare increased $60 million in the third quarter of 2021 and decreased $4 million in the nine months ended September 30, 2021, when compared to the same periods in 2020. The year-over-year changes in margin are driven by an increase in premium revenue and changes in the MCR.
The Medicare MCR decreased to 82.8% in the third quarter of 2021, from 85.6% in the third quarter of 2020, mainly due to a favorable impact from the net effect of COVID, including utilization curtailment and corridor related adjustments. The Medicare MCR increased to 86.8% in the nine months ended September 30, 2021, compared to 82.4% in the nine months ended September 30, 2020, primarily driven by the net effect of COVID, including higher direct COVID medical costs, and the temporary industry-wide challenge of risk scores that do not fully reflect the acuity of our membership. COVID-related utilization curtailment drove a lower MCR for the nine months ended September 30, 2020.
Marketplace
Marketplace premium revenue increased $397 million in the third quarter of 2021 compared to the third quarter of 2020 and increased $1,048 million in the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was mainly due to higher membership, partially offset by a decrease in premium revenue PMPM. Our Marketplace membership as of September 30, 2021, amounted to 719,000 members, representing growth of 81,000 members sequentially compared to June 30, 2021, and substantially exceeding our expectations. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, and the extended open enrollment period. The decrease in premium revenue PMPM was mainly driven by changes in business mix, with an increase of members in the bronze metal tier.
The Marketplace medical margin decreased $2 million in the third quarter of 2021 when compared with the third quarter of 2020, due to the increase in the MCR, partially offset by the impact of increased premium revenue. The Marketplace medical margin increased $59 million in the nine months ended September 30, 2021 when compared with the nine months ended September 30, 2020, primarily due to the increase in membership and premiums, mostly offset by an increase in the MCR compared to 2020.
The Marketplace MCR increased to 91.3% in the third quarter of 2021, compared to 81.6% in the third quarter of 2020, and increased to 84.8% in the nine months ended September 30, 2021, compared to 76.0% in the nine months ended September 30, 2020. The increase for both periods resulted mainly from higher direct COVID medical costs, due to continued COVID utilization pressure in many of our Marketplace geographies, and non-COVID utilization by members enrolled through the special enrollment period.
Other
The Other segment includes service revenues and costs associated with the long-term services and supports consultative services we now provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations for the third quarter and nine months ended September 30, 2021 and 2020.

LIQUIDITY AND FINANCIAL CONDITION
LIQUIDITY
We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.
We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity. In the first half of 2021, we did not experience noticeable delays to, or changes in, the timing or level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below in “Future Sources and Uses of Liquidity—Future Uses—Potential Impact of COVID-19 Pandemic.”
A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 31

general corporate purposes. In the third quarter and nine months ended September 30, 2021, the parent company received $127 million and $346 million, respectively, in dividends and return of capital from the regulated health plan subsidiaries. See further discussion of dividends below in “Future Sources and Uses of Liquidity—Future Sources.”
The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans. In the third quarter and nine months ended September 30, 2021, the parent company contributed capital of $23 million and $110 million, respectively, to the regulated health plan subsidiaries.
Cash, cash equivalents and investments at the parent company amounted to $703 million and $644 million as of September 30, 2021, and December 31, 2020, respectively. The increase as of September 30, 2021, was mainly due to the dividends received from the regulated health plan subsidiaries in the nine months ended September 30, 2021, partially offset by the capital contributed to regulated health plan subsidiaries and our share repurchase program. In the first quarter of 2021, we purchased an aggregate of approximately 577,000 shares for $122 million, and we also paid $6 million to settle shares purchased in late December 2020.
Investments
After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations.
Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels.
We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated AA. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets.
Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets.
Cash Flow Activities
Our cash flows are summarized as follows:
Nine Months Ended September 30,
20212020Change
(In millions)
Net cash provided by operating activities$1,522 $599 $923 
Net cash (used in) provided by investing activities(1,106)98 (1,204)
Net cash (used in) provided by financing activities(204)61 (265)
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents
$212 $758 $(546)
Operating Activities
We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month’s premium payment.
Net cash provided by operations for the nine months ended September 30, 2021 was $1,522 million, compared with $599 million in the nine months ended September 30, 2020. The $923 million increase in cash flow was due to the growth in operations and the net impact of timing differences in government receivables and payables.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 32

Investing Activities
Net cash used in investing activities was $1,106 million in the nine months ended September 30, 2021, compared with $98 million provided by investing activities in the nine months ended September 30, 2020, a decrease in cash flow of $1,204 million. This decrease in cash flow was primarily due to increased purchases of investments in the nine months ended September 30, 2021.
Financing Activities
Net cash used in financing activities was $204 million in the nine months ended September 30, 2021, compared with $61 million provided by financing activities in the nine months ended September 30, 2020, a decrease in cash flow of $265 million. In the nine months ended September 30, 2021, financing cash outflows included common stock purchases of $128 million and $52 million for common stock withheld to settle employee tax obligations. Additionally, we paid $23 million to settle contingent consideration liabilities relating to our Kentucky Passport acquisition that closed in 2020, $20 million of which has been presented as a financing cash outflow. In the nine months ended September 30, 2020, financing cash inflows included $380 million borrowed under the term loan facility and net proceeds of $189 million related to the repayment of the term loan facility and issuance of senior notes. This was offset by financing cash outflows related to common stock purchases of $453 million, common stock withheld to settle employee tax obligations of $8 million, and other financing outflows of $47 million.

FINANCIAL CONDITION
We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in “Future Sources and Uses of Liquidity—Future Sources,” and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months.
On a consolidated basis, at September 30, 2021, our working capital was $3.3 billion, compared with $2.9 billion at December 31, 2020. At September 30, 2021, our cash and investments amounted to $7.4 billion, compared with $6.2 billion at December 31, 2020.
Regulatory Capital and Dividend Restrictions
Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately $1.9 billion at September 30, 2021, compared with $1.5 billion at December 31, 2020. The aggregate capital and surplus of our wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates.
Under applicable regulatory requirements, the amount of dividends that may be paid by our wholly owned subsidiaries without prior approval by regulatory authorities as of September 30, 2021, was approximately $182 million in the aggregate. The subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.
Based on our cash and investments balances as of September 30, 2021, management believes that our regulated wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.
Debt Ratings
Each of our high-yield senior notes is rated “BB-” by Standard & Poor’s, and “Ba3” by Moody’s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our borrowing costs.
Financial Covenants
The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement.
In addition, the indentures governing each of our outstanding high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of September 30, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 33


FUTURE SOURCES AND USES OF LIQUIDITY
Future Sources
Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.
Potential Impact of COVID-19 Pandemic. Excluding acquisitions and our exit from Puerto Rico, we have added over 700,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-January 2022.
Dividends from Subsidiaries. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.
Credit Agreement Borrowing Capacity. As of September 30, 2021, we had available borrowing capacity of $1 billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15 million swingline sub-facility and a $100 million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500 million, plus an unlimited amount of such term loans as long as our consolidated net leverage ratio is not greater than a defined maximum. See further discussion in the Notes to Consolidated Financial Statements, Note 8, “Debt.”
Future Uses
Common Stock Purchases. In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program immediately supersedes the stock purchase program previously approved by our board of directors in September 2020. This new program will be funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of October 28, 2021, $500 million remained available to purchase our common stock under this program through December 31, 2022.
Acquisitions. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.
On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.
On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.
Potential Impact of COVID-19 Pandemic. As described above in “Trends and Uncertainties,” we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 34

retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.
It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Regulatory Capital Requirements and Dividend Restrictions. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.

CONTRACTUAL OBLIGATIONS
A summary of future obligations under our various contractual obligations and commitments as of December 31, 2020, was disclosed in our 2020 Annual Report on Form 10-K.
There were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the nine months ended September 30, 2021.

CRITICAL ACCOUNTING ESTIMATES
When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:
Medical claims and benefits payable. Refer to Notes to Consolidated Financial Statements, Note 7, “Medical Claims and Benefits Payable,” for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, in the nine months ended September 30, 2021 there have been no significant changes to our disclosure reported in “Critical Accounting Estimates” in our 2020 Annual Report on Form 10-K.
Contractual provisions that may adjust or limit revenue or profit. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”
Quality incentives. In the nine months ended September 30, 2021, there have been no significant changes to our disclosure reported in “Critical Accounting Estimates” in our 2020 Annual Report on Form 10-K.
Business combinations, goodwill, and intangible assets, net. In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. Such reportable operating segments also now constitute our reporting units in the annual assessment of goodwill impairment. Refer to Notes to Consolidated Financial Statements, Note 10, “Segments,” for a presentation of goodwill, and intangibles assets, net, by reportable segment, and “Critical Accounting Estimates,” in our 2020 Annual Report on Form 10-K, for further information.

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 35

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.
Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at September 30, 2021, the fair value of our fixed income investments would decrease by approximately $67 million. Declines in interest rates over time will reduce our investment income.
For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, “Fair Value Measurements,” and Note 6, “Investments.”
Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, “Debt.”

CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.
Changes in Internal Control Over Financial Reporting. There has been no change in our internal control over financial reporting during the nine months ended September 30, 2021, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

LEGAL PROCEEDINGS
For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, “Commitments and Contingencies.”

RISK FACTORS
Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed under the caption “Risk Factors,” in our 2020 Annual Report on Form 10-K. The risk factors described in our 2020 Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price.

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 36

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ISSUER PURCHASES OF EQUITY SECURITIES
Purchases of common stock made by us, or on our behalf, during the third quarter of 2021, including shares withheld by us to satisfy our employees’ income tax obligations, are set forth below:
Total Number
of Shares
Purchased (1)
Average Price Paid per ShareTotal Number of Shares
Purchased as Part of
Publicly 
Announced 
Plans or
Programs
Approximate Dollar Value
of Shares that May Yet Be Purchased Under the Plans or Programs (2)
July 1 - July 312,000 $256.05 — $219,000,000 
August 1 - August 31— $— — $219,000,000 
September 1 - September 30 — $— — $500,000,000 
Total2,000 $256.05 — 
_______________________
(1)During the third quarter of 2021, we withheld approximately 2,000 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan.
(2)For further information on our stock repurchase programs, refer to Note 9, “Stockholders' Equity.”
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 37

INDEX TO EXHIBITS 
Exhibit No.TitleMethod of Filing
10.1Filed as Exhibit 10.1 to registrant’s Form 8-K filed September 9, 2021.
31.1Filed herewith.
31.2Filed herewith.
32.1Filed herewith.
32.2Filed herewith.
101.INS Inline XBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.Filed herewith.
101.SCH Inline XBRL Taxonomy Extension Schema Document.Filed herewith.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.Filed herewith.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.Filed herewith.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.Filed herewith.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith.
104Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)Filed herewith.

Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 38

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MOLINA HEALTHCARE, INC.
(Registrant)
Dated: October 28, 2021/s/ JOSEPH M. ZUBRETSKY
Joseph M. Zubretsky
Chief Executive Officer
(Principal Executive Officer)
Dated: October 28, 2021/s/ MARK L. KEIM
Mark L. Keim
Chief Financial Officer and Treasurer
(Principal Financial Officer)
Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 39
EX-31.1 2 moh3q21_ex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a)/15d-14(a)
UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED
I, Joseph M. Zubretsky, certify that:
1. I have reviewed the report on Form 10-Q for the period ended September 30, 2021, of Molina Healthcare, Inc.;
2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation; and
(d) Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 
Dated: October 28, 2021 /s/ Joseph M. Zubretsky
  Joseph M. Zubretsky
  
Chief Executive Officer, President and Director

EX-31.2 3 moh3q21_ex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a)/15d-14(a)
UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED
I, Mark L. Keim, certify that:
1. I have reviewed the report on Form 10-Q for the period ended September 30, 2021, of Molina Healthcare, Inc.;
2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation; and
(d) Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: October 28, 2021 /s/ Mark L. Keim
  Mark L. Keim
  Chief Financial Officer and Treasurer


EX-32.1 4 moh3q21_ex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATE PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the report of Molina Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 (the “Report”), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 28, 2021/s/ Joseph M. Zubretsky
Joseph M. Zubretsky
Chief Executive Officer, President and Director


EX-32.2 5 moh3q21_ex322.htm EX-32.2 Document

EXHIBIT 32.2
CERTIFICATE PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the report of Molina Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 (the “Report”), I, Mark L. Keim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 28, 2021 /s/ Mark L. Keim
  Mark L. Keim
  Chief Financial Officer and Treasurer




EX-101.SCH 6 moh-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Significant Accounting Policies - Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2110103 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Net Income per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2115105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Investments - Summary of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Investments - Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2126107 - Disclosure - Medical Claims and Benefits Payable link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Medical Claims and Benefits Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2131108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2135109 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details) link:presentationLink link:calculationLink link:definitionLink 2140111 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 moh-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 moh-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 moh-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Common stock authorized Stock Repurchase Program, Authorized Amount Risk adjustment, net payable, prior year Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net Income (Loss) Attributable to Parent Receivables Receivable [Policy Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Other Other Claims Payable Other Claims Payable Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Magellan complete care Magellan Complete Care [Member] Magellan Complete Care [Member] Receivable Type [Axis] Receivable Type [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Contingent consideration liabilities settled Payment for Contingent Consideration Liability, Financing Activities Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Risk adjustment receivable Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable Other assets Other Assets, Noncurrent Amounts due government agencies Medical Premium Liability Due To Agency Medical Premium Liability Due To Agency Medical Premium Liability Due to Agency Segments [Axis] Segments [Axis] Net increase in cash, cash equivalents, and restricted cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income taxes Increase (Decrease) in Income Taxes Payable Goodwill Goodwill, Purchase Accounting Adjustments Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Proceeds from senior notes offering, net of issuance costs Proceeds from Issuance of Senior Long-term Debt Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Stock purchases (in shares) Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Structured Securities Structured Securities [Member] Structured Securities [Member] Contractual maturities of investments Investments Classified by Contractual Maturity Date [Table Text Block] Extension option Health Plan, Extension Option, Period Health Plan, Extension Option, Period Other operating Segment Reconciling Items [Member] Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding Preferred Stock, Value, Issued Insurance Claims Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Entity Address, City or Town Entity Address, City or Town Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Fair value of debt Debt Instrument, Fair Value Disclosure Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Texas Acquisition - Medicaid and Medicare Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member] Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan Available-for-sale investments Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Health insurer fee reimbursement receivables Health Insurer Fee Reimbursement Receivables [Member] Health Insurer Fee Reimbursement Receivables [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Interactive Data Current Entity Interactive Data Current Minimum MLR Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold Prior period claims, favorable development Prior years Prior Year Claims and Claims Adjustment Expense Net income per share - Basic (in dollars per share) Earnings Per Share, Basic Medicaid: Amounts Due To Government Agencies, Medicaid Program [Abstract] Amounts Due To Government Agencies, Medicaid Program [Abstract] Hidalgo Service Area Hidalgo Service Area [Member] Hidalgo Service Area Schedule Of Premium Revenue By Health Plan Type [Table] Schedule of Premium Revenue by Health Plan Type [Table] Schedule of premium revenue by health plan type. Document Type Document Type Consolidation and Interim Financial Information Consolidation And Interim Financial Information, Policy [Policy Text Block] Consolidation And Interim Financial Information, Policy [Policy Text Block] Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Number of states with programs Number Of States With Government-Sponsored Healthcare Programs Number Of States With Government-Sponsored Healthcare Programs Fair Value Measurement [Domain] Fair Value Measurement [Domain] Entity Current Reporting Status Entity Current Reporting Status Payable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Receivables Total receivables Receivables, Net, Current Total Purchase price Business Combination, Consideration Transferred Total assets Assets, Fair Value Disclosure (Level 1) Fair Value, Inputs, Level 1 [Member] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Other, net Other Operating Activities, Cash Flow Statement Document Transition Report Document Transition Report Average maturity period (less than) Investments, Average Maturity Period Investments, Average Maturity Period Total liabilities and stockholders’ equity Liabilities and Equity Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Deferred revenue Contract with Customer, Liability, Current Amortized Cost, Due in one year or less Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One Contract term Health Plan, Contract Term Health Plan, Contract Term Hidalgo, Tarrant and Northeast Service Areas Hidalgo, Tarrant and Northeast Service Areas [Member] Hidalgo, Tarrant and Northeast Service Areas LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Risk adjustment, net payable Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable Accounts payable, accrued liabilities and other Accounts Payable and Accrued Liabilities, Current Medicare Medicare [Member] Medicare Net Income per Share Earnings Per Share [Text Block] Government receivables Government Receivables [Member] Government Receivables [Member] Average cost (USD per share) Treasury Stock Acquired, Average Cost Per Share Minimum Minimum [Member] Gross realized investment gains Debt Securities, Available-for-sale, Realized Gain Organization and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Investments Marketable Securities, Current Total margin Gross Profit Amount outstanding under letter of credit Long-term Line of Credit Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Other comprehensive loss income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Health Plans Medicaid Health Plans [Member] Health plans. Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Gross unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Due after ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Change in acquired balances Change In Acquired Balances Change In Acquired Balances Trading Symbol Trading Symbol Schedule of Premium Revenue by Health Plan Type [Line Items] Schedule of Premium Revenue by Health Plan Type [Line Items] Schedule of premium revenue by health plan type. U.S. Treasury notes US Treasury Notes Securities [Member] Outstanding equity interests Business Acquisition, Percentage of Voting Interests Acquired Deferred income taxes Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] Receivable [Domain] Receivable [Domain] Medical claims and benefits payable Increase (Decrease) in Health Care Insurance Liabilities General and administrative expenses General and Administrative Expense Net cash paid in business combinations Net cash paid in business combinations Payments to Acquire Businesses, Net of Cash Acquired Beginning Balance (in shares) Ending Balance (in shares) Shares outstanding at the beginning of the period (in shares) Shares, Outstanding Line of Credit Line of Credit [Member] Senior notes Senior Notes [Member] Reduction in premiums Increase (Decrease) in Premiums Receivable (Level 3) Fair Value, Inputs, Level 3 [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Total other expenses, net Other expenses, net Nonoperating Income (Expense) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Mortgage-backed securities Mortgage-backed securities Commercial Mortgage Backed Securities [Member] Estimated Fair Value Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value Business Combinations Business Combination Disclosure [Text Block] 5.375% Notes Senior Notes Due 2022 [Member] Senior Notes Due 2022 [Member] Magellan Complete Care acquisition opening balance Complete Care Receivables [Member] Complete Care Receivables Document Period End Date Document Period End Date Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stock-based compensation (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total operating expenses Less: other operating expenses Costs and Expenses Amortized Cost, Due one year through five years Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five Entity Registrant Name Entity Registrant Name Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] 4.375% Notes 4.375% Senior Notes [Member] 4.375% Senior Notes Receivables Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Less: effect of income taxes OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Financial Instrument [Axis] Financial Instrument [Axis] Debt securities, available-for-sale Estimated Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Fee-for-service claims incurred but not paid (“IBNP”) Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Other Amounts Due to Government Agencies, Other Amounts Due to Government Agencies, Other Consolidation Items [Domain] Consolidation Items [Domain] Equity [Abstract] Equity [Abstract] Carrying Amount Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Estimated Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common Stock Common Stock [Member] Medical Claims and Benefits Payable Medical Claims And Benefits Payable [Text Block] Medical claims and benefits payable. Segments Segment Reporting Disclosure [Text Block] Operating income Operating Income (Loss) Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Non-risk provider payables Medical Claims And Benefits Payable Medical Claims and Benefits Payable Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Gross unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Components of medical care costs related to: Components Of Medical Care Costs [Abstract] Components of medical care costs. Share-based compensation Share-based Payment Arrangement, Noncash Expense Minimum MLR and profit sharing Medical Premiums Liability, Medical Care Costs Threshold Medical Premiums Liability, Medical Care Costs Threshold Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Other Other Receivables [Member] Other Receivables [Member] Medicaid Medicaid [Member] Medicaid Proceeds from borrowings under term loan facility Proceeds from Lines of Credit Other expense, net Other Nonoperating Income (Expense) Other, net Payments for (Proceeds from) Other Investing Activities Purchases of property, equipment and capitalized software Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Total liabilities Liabilities Legal Entity [Axis] Legal Entity [Axis] Receivables Increase (Decrease) in Receivables Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Total stockholders’ equity Stockholders' Equity Attributable to Parent Current year Current Year Claims and Claims Adjustment Expense 3.875% Notes Three Point Eight Seven Five Percent Senior Notes [Member] Three Point Eight Seven Five Percent Senior Notes Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounts payable, accrued liabilities and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Debt securities held to maturity Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss Loss on debt repayment Gain (Loss) on Extinguishment of Debt Risk adjustment, net payable, current year Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year Common stock purchases Payments to settle shares purchased Payments for Repurchase of Common Stock Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Health insurer fees Health Care Organization, Insurer Fee Expense Health Care Organization, Insurer Fee Expense Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Face amount Debt Instrument, Face Amount Interest expense Interest Expense Other revenue Interest and Dividend Income, Operating Amounts due to government agencies Reserves Reported to Other Agencies [Table Text Block] Marketplace: Amounts Due To Government Agencies, Marketplace Program [Abstract] Amounts Due To Government Agencies, Marketplace Program [Abstract] City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Operating segments Operating Segments [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Restricted cash and cash equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Fair Value Estimate of Fair Value Measurement [Member] Passport Health Plan, Inc. Passport Health Plan Inc [Member] Passport Health Plan Inc Repayment of term loan facility Repayments of Lines of Credit Beginning Balance Ending Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total current assets Assets, Current Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Operating segment information Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity File Number Entity File Number Common stock purchases Repurchased of common stock Stock Repurchased During Period, Value Estimated Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Maturity period (less than) Investments, Maturity Period Investments, Maturity Period Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Entity Small Business Entity Small Business Magellan Complete Care acquisition opening balance Amounts Due to Government Agencies, Business Combination Amounts Due to Government Agencies, Business Combination Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Common stock purchases (in shares) Repurchased of common stock (in shares) Stock Repurchased During Period, Shares Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Payments for medical care costs related to: Payments For Medical Care Costs [Abstract] Payments for medical care costs. Statement [Line Items] Statement [Line Items] Property, equipment, and capitalized software, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Deferred debt issuance costs Debt Issuance Costs, Noncurrent, Net Share-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Health insurer fees reimbursed Health Care Organization, Insurer Fee Revenue Health Care Organization, Insurer Fee Revenue Paid to seller Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Capitation payable Capitation Claims Payable Capitation Claims Payable Debt Disclosure [Abstract] Debt Disclosure [Abstract] Other Amounts Due To Government Agencies, Medicaid, Other Amounts Due To Government Agencies, Medicaid, Other Entity Address, State or Province Entity Address, State or Province Purchases of investments Payments to Acquire Marketable Securities Income before income tax expense Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (Level 2) Fair Value, Inputs, Level 2 [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity [Domain] Entity [Domain] Number of members covered Number of Members Covered Number of Members Covered Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Use of Estimates Use of Estimates, Policy [Policy Text Block] Summary of denominators for the computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Non-current portion of long-term debt Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount Local Phone Number Local Phone Number Other comprehensive (loss) income, net of tax Other comprehensive income (loss), net Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Risk adjustment and Part D risk sharing Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing Total assets Assets Common stock, shares authorized (in shares) Common Stock, Shares Authorized Geographical [Domain] Geographical [Domain] Restricted investments Restricted Investments, Noncurrent Schedule of liability for unpaid claims and claims adjustment expense Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Debt instrument, interest rate, stated percentage Percentage of contractual interest rate on notes Debt Instrument, Interest Rate, Stated Percentage Schedule of receivables Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Premium revenue Premiums Earned, Net Contingent consideration liabilities Business Combination, Contingent Consideration, Liability Credit facility Revolving Credit Facility [Member] Significant Accounting Policies Significant Accounting Policies [Text Block] Minimum MLR and profit sharing Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other Other Segments [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Change in non-risk and other provider payables Medical Claims And Benefits Payable, Adjustments, Change In Provider Medical Claims and Benefits Payable, Adjustments, Change in Provider Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Entity Tax Identification Number Entity Tax Identification Number Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Geographical [Axis] Geographical [Axis] Denominator for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Net income per share - Diluted (in dollars per share) Earnings Per Share, Diluted New York NEW YORK Segments [Domain] Segments [Domain] Amounts due government agencies Increase (Decrease) In Medical Premium Liability Due To Agency Increase (Decrease) in Medical Premium Liability Due to Agency Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Pharmacy payable Pharmacy Claims Payable Pharmacy Claims Payable Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Components of the change in medical claims and benefits payable Components Of Change In Medical Claims And Benefits Payable [Table Text Block] Components Of Change In Medical Claims And Benefits Payable [Table Text Block] Other Other Cost and Expense, Operating Corporate debt securities Corporate Debt Securities [Member] Fair Value Measurements Fair Value Disclosures [Text Block] New York Acquisition—Medicaid New York Acquisition—Medicaid [Member] New York Acquisition—Medicaid Depreciation and amortization Depreciation, Depletion and Amortization Fair value measurements of senior notes Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair value of assets measured on recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Premium tax revenue Health Care Organization, Premium Tax Revenue Health Care Organization, Premium Tax Revenue Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Premium tax expenses Premium Tax Expenses An assessment levied by a state government on the net premium income collected. Medical care costs Cost of Goods and Services Sold Revenue: Revenues [Abstract] Total Number of Positions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Stock-based compensation (in shares) Weighted Average Number of Shares, Share Based Compensation Weighted Average Number of Shares, Share Based Compensation Other Other Securities [Member] Other Securities Medicare: Amounts Due To Government Agencies Medicare Program [Abstract] Amounts Due To Government Agencies Medicare Program Debt term Debt Instrument, Term Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Due in one year or less Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Investment income Net Investment Income Other long-term liabilities Other Liabilities, Noncurrent AgeWell New York AgeWell New York [Member] AgeWell New York Long term debt Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Document Quarterly Report Document Quarterly Report Total revenue Total revenue Revenues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Operating expenses: Costs and Expenses [Abstract] Long-term debt Total Long-term Debt, Excluding Current Maturities Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Goodwill, and intangible assets, net Total Intangible Assets, Net (Including Goodwill) Net income per share: Earnings Per Share, Basic and Diluted [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Marketable Securities Other Other Medicare Program Other Medicare Program Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Risk adjustment payable Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable) Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable) Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period Cash, cash equivalents, and restricted cash and cash equivalents at end of period Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Current assets: Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other, net Proceeds from (Payments for) Other Financing Activities Entity Central Index Key Entity Central Index Key Income Taxes Income Tax, Policy [Policy Text Block] Security Exchange Name Security Exchange Name Unrealized investment (loss) income OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Medical claims and benefits payable Total Medical claims and benefits payable, beginning balance Medical claims and benefits payable, ending balance Liability for Claims and Claims Adjustment Expense Premium Revenue Recognition and Premiums Receivable Revenue from Contract with Customer [Policy Text Block] Denominator for diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted COVID-19 COVID-19 [Member] COVID-19 Weighted-average number of shares issued: Weighted Average Number of Shares Outstanding, Basic [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Recognized loss Gain (Loss) on Fair Value Hedges Recognized in Earnings Measurement Basis [Axis] Measurement Basis [Axis] Total medical care costs Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other expenses, net: Nonoperating Income (Expense) [Abstract] Number of members eligible for the health care programs, approximately Business Combination, Number Of Members Eligible For The Health Care Programs Number of members eligible for the health care programs. Class of Stock [Line Items] Class of Stock [Line Items] Credit Facility [Axis] Credit Facility [Axis] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Portion at fair value measurement Portion at Fair Value Measurement [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Marketplace Marketplace [Member] Marketplace Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Total current liabilities Liabilities, Current Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Municipal securities Municipal Securities [Member] Municipal securities. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Pharmacy rebate receivables Pharmacy Rebate Receivables [Member] Pharmacy Rebate Receivables [Member] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Total paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Asset-backed securities Asset-backed Securities [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Termination of warrants Adjustments to Additional Paid in Capital, Other Subsequent event Subsequent Event [Member] Cover [Abstract] Cover [Abstract] Finance lease liabilities Finance Lease, Liability, Noncurrent Goodwill Goodwill Due after ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2021, and 59 million shares at December 31, 2020 Common Stock, Value, Outstanding Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Risk adjustment Amounts Due to Government Agencies, Risk Adjustment Amounts Due to Government Agencies, Risk Adjustment Amounts due government agencies Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies Common stock withheld to settle employee tax obligations Common Stock Withheld to Settle Employee Tax Obligations Common Stock Withheld to Settle Employee Tax Obligations Debt Long-term Debt [Text Block] Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year EX-101.PRE 10 moh-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 moh-20210930_g1.jpg GRAPHIC begin 644 moh-20210930_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1$&17AI9@ 34T *@ @ ! $[ ( M 4 (2H=I 0 ! (7IR= $ H 0UNH< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z#IX;7!M971A/@T*(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04& M!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H M*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ MP@(G P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q]5\5Z)HKF/4-0C24 M=8ER[#ZA6QE;1M(D\N?'^D3J>4S_"OH<=3VKRLDL26.23DD]Z M[J.$YUS3/G\=G"H3=.BKM;OH>WP_$CPS-+L-Z\7. TD+8/Y#^=='9WMKJ%NL M]C<1W$3='C8,/TKYLK2T37K_ ,/WRW.G3%>?GC/*2#T(_P FMIX*-O<9Q4,^ MJ&_M.%<8=#U1AU4UHUYC33LSZN$XSBI1=TPHHKS M/XA>.9H+F31M&F,93Y;F=#\V?[BGM[G\/6KITY5)&DY.3S1 M7HK!0MJV?,2S[$-@P/XBI:^?/#WB2_\ M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ' MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07MRMG87%T_W M8(FD/T S_2IZH:]"USX6TE11[E"*<=7J1-M0;6Y\\W-Q+=W4MS<,7 MEF/BTE5T/NI ) KYREE>:5Y96+R.Q9F/4D]37T#XL@:X\(:I&F2WV9V '? S_2 MOGRNG IE@HHHKO/FPKTSX1:BY;4--=LIA9T'H?NM_P"RUYG7 M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]_M+S/V2Z@GQU\J0-C M\JGHV!--704444#/"/&WAR3P]K\JI&19W#&2W;'&.Z_4=/IBNSU&$2Q-SZ%3V(/8UYCJWPHU&"4MH]Q'=1=DE.QQ_0_7CZ5ZU#%1<;3=F?& MX_**L*CG05XOIU1P%%=9#\-/$TLFV2SCA&?O23H1_P".DFNU\,?#2TTB=+O5 M9%O;E"&1 ,1H?7G[Q^N/I6L\33@M[G'0RO%5I6Y6EW>A/\-_#KZ+H;75VFRZ MO2'*GJB#[H^O)/XCTKLJ**\>C)Z?4=#7O]9VM:'8Z_I[6FHQ;TZJP.&0^H/K6N'K> MREKLSCS' _7*=EI);?Y'SM17=ZI\*=6MI6.ES0WD6?E#-Y;CZYX_6L^#X:>) MII-LEG' /[TDZ$?^.DFO65>DU?F/CY9?BHRY73?W?JW_#[PZ^@^'] MUTFR[NR))5/5!_"I^@R?J357PO\ #BST29+S49%O;Q3E!M_=QGU /4^Y_*NU MKS\3B%-(ZEJM]K%V;G4;F2>0]"QX7V Z >PKJ_BM=/-XKC M@).R"V4 >Y))/\ORKB*]G"TE&"EU9\/FV*G5Q$J=_=CI8?#-+;S++!(\4B'* MNC$%3[$5ZS\/O&TVL2'2M7<-=JNZ&;O*!U!]QUSW&?3GR.M'P]=/9>)-.N(R M04N4SCN-P!'XC-:5J2J0=]SEP.*GAJR:>CW1]$U@:YK6M:0K2V^@+?VZ\EH+ ML[@/=-F?RS6_17B1:3U5S[ZI&4XVC*S^7ZGF1^,.#SH7/_7W_P#84?\ "XO^ MH%_Y.?\ V%:GCOP-#JEK+J6E0B._C!=T0<3COQ_>]^_2O'J].E2H58W2_,^3 MQF+S'"5.2<].CLM?P/3?^%Q?]0+_ ,G/_L*5?C"I8;]$('1^5?.U.21XI%>-F1U.593@@UG+!P?PNQUT<\Q$7^\2DON?]?(] MYUS6=:TE6EMM!74+Z;,_EFN1_X7#@\Z%S_U]_\ V%5O"/Q*G@FC ML?$,GG0,0J71^\G^]ZCWZ_6MWQSX(@U>SDU328U2^1=[+&.+@?\ Q7H>_2N= M4X4YWYGA_VOC?Y_P7^1Z$I/H7'.,9%ZRO\ )?H?1&E^(=)UD?\ $MOX9VQG M8#AQ_P !/-:5?,Z2/%(KQLR.IRK*<$'VKT'PC\2KBVFCLO$,AFMV.%NCR\?^ M]_>'OU^M*O$-MX5\+:AK5X1 MY=I"7"D_??HJ_BQ _&@#S_QS\=K#P9XLGT--(?46MXU,LR7(3:Y&=F-IZ CG M/4XQQ79> /&4?COPI'K45F;,/*\1A,GF8VG&8P[\YP.Y!]*!'3^*O'/A[P9:^=K^HQP.PS';K\T MLG^Z@Y_'I[UY#K/[38$C)X>\/[D_AFOIL$_\ 7_XJO"KV^U#7-5>ZOIYKV]N M7^9W)=W8]!_0"OICX8?!/3/#VGPZEXIM(;_6) '\J4!X[7T4 \,P[MV/3U(, MX'_AHSQL\;2Q:-I!BY.[[-,0!]?,J[IO[3>IHRC6/#UI.O\ $;69HC^ ;=7T M6JA%"H J@8 P *X?QS\)O#GC2SE9K6.PU,@F.^MXPK;O]L#[X^O/H10 SP? M\8_"?C"5+:"[:POWX6UO0$+GT5LE6^F<^U=Y7PEKVAWWAK7KK2=4C\JZM9-C M@=#W# ]P1@@^AKW#X(_%RXNKR#PIXHN&F:0;+"[D.6)_YY.3US_"?P[B@+'O MM>??$OXJI\.+S389=(;4%ODD8LMQY93:5&,;3G.[U%>@UX%^U#&QB\,2 ?*I MNE)SW/E8_D:!$C?M/VH4[/"TQ;' -Z #^.RO;=(O_P"U-%L=0,7D_:[>.?R] MV[9N4-C.!G&?2O@ROO+18VAT&PB?&Y+:-3CU"B@;+M%%% CSKXE?%E/ASJEA M:S:,]^EY"TGF+<>7M(.,8VG/YUQ;_M/VH0^7X6F9NP:^ !_'953]J"(B[\-2 M\;62Y4#OD&/_ !%>"4#/O>PNOMVFVUWL\OSX4EV9SMW '&>_6L[Q=KY\+>$[ M_6UM?MGV*,2&#S-F\9 /S8..#GIVK3LHVBL+>-QM9(E4CT(%>:?^TQI=QJ=O#?:#/:6LC[9;D7(D,0_O;0HR/7G./7I7M< M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU'?$4W_$GF?%O._\ MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281 MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\ MR+>I_P#7I+_Z :^3?@E$)OC)H*L2 &F;CV@D/]*!GV%1110(*\6\8?M!CPSX MPU+1K/1(]1BLW\H3_:C'^\ &X$;3T;(_"O4/%_B"+PMX/U/6IMO^B0,R*W1I M#PB_BQ _&OAZXGENKF6XN',DTKEY';JS$Y)_.@:/MWP5XGB\8^#]/UR%!&;F M/]Y$#GRY 2K+^8/X8K=KP#]FGQ-_R%/#,[_]/ML"?HL@_P#0#CZU[_0(XG6_ MB-!IMV8;."V>%97A-W?W36\,DB??2,K'(SE>YV@ Y&<@XU_#GBJ+79#;RP"V MNA"MP@28317$3' DBD'WUSP> 0>H&1GS/6](UK6-)T+0O#Q\C6]#ENUNV;;F M,F-PDA#\E9=P(8 _>/<5TO@M8Y[KPY8V6G-8-H5A-'?P^9Y@MY'V 0[P2&+% M2^,Y "YQD4#/1J***!!1110 4444 %%%% 'EOQ:TB075IJ\:DQ,GD2D?PD$E M3^.3^5>;U])WEG;ZA9R6MY$LT$J[71AU%>8:Q\)KN.=GT2ZCFA)R(YSM=?;( M&#^E>GAL1%1Y)]#Y3-,LJRJNM15T]T>=UT7@72)-7\66@528K9Q/*V. %.0/ MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\ MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@= M&^;'ZU] UX/X]_Y'K4_]]?\ T!:[L%\;7D?/9\E["+\_T9SM%%%>J?'A1110 M 5[-\,=8DU+PTUK.Q>2Q?RP2?X",K^7(^@%>,UZ5\'G(GU9.Q6(_D7_QKEQ< M4Z3?8]?)ZCABXI=;K\+G'^,+..Q\8:E!" J"8LH'0;ANQ^M8M=%X]_Y'K4_] M]?\ T!:YVMZ>L%Z'!BDE7FEW?YA1115G.%%%% 'LGPOUA]0\./9S-NDL7"*3 M_P \SRO\F'T KMJ\N^#Y/VK51VV1HUXF)BHU6D??Y74E4P<'+T^YV.% M^-%]]@^$.N.IPTD:0CWWR*I_0FOCPJP4,5(#="1UKZ?_ &D;[[/\.K2T4_-= M:@@(]55')_7;7 _\( -8_9KL-:LXD5\\_M(>,#->6?A*S?Y(<75YM/5R/D0 M_0$MC_:7TKW3Q#KEKX:\.WVL:@<06<)D89P6/91[DX ]S7S+\+M$N_B5\6Y= M;UD>;!;3?;[MOX2^[]W&/;(Z?W5(H \PG@EM;B2WN$:.6)RCHPY5@<$'\:][ M_9@O!N\1V3'DBWE0?]]AO_9:\H^)=K]C^*'B.+UU"63_ +[8M_[-7=?LUWGD M_$"_M2<+<:+O$=S MXM\5W^M7A(:ZE)1"?]6@X5?P4 5];?%>\>Q^%'B&6,D,UH8LCT$?LPVJKIGB&[P-\DT M,6?0*K'_ -FKW>@&%%%% CP#]ICP[&JZ1XCA0+(S&RG8#[W!>/\ D_Z>E>!0 MS26\\"=? M_P"$H\$:3K)QYEU;JTN.@D'RN!_P(&O)?VG_ /D&^'?^NT_\DKIOV>;EI_A3 M'&W2WO9HUY[<-_-C7,_M/_\ (-\._P#7:?\ DE NI\[U][Z?_P @VV_ZXI_( M5\$5][Z?_P @VV_ZXI_(4 RQ1110(\ _:B_YE;_M[_\ :-?/]?0'[47_ #*W M_;W_ .T:^?Z"D??] MXQ_6@D^0M)\,ZGKFEZI?Z7 9X]+C66Y5?O!&)&X#OC&3[<]JR:]W_9AYU+Q' MG_GC!_-ZJ?&OX1?V-)/XG\,0?\2]VW7=I&O_ !['NZ@?P'N/X3[= HN?!#XN M?96@\)^)[C]P2(]/NG/^K/:)CZ?W3VZ=,8^AJ^ *^C_@G\7/[4C@\+>)KC_3 MD 2QNG_Y;J!Q&Q_OCL>_UZ@F>RZM$)]%O8B<"2WD4D=LJ17RG\!$W?%_33MS MMAG.<=/W3#/Z_K7U??\ _(-N?^N+_P C7RQ^SW_R5B#_ *])OY"@#ZOHHIDL ML<$+RS.J1QJ6=V. H'))H$>#_M*^*=EOIOA>V?YI#]LN@#_",K&#]3N./85X M_P"(O!>H>'/#F@:Q> ^3K5NTR#;_ *LAN ?JA1A]3Z5M$S?%KXV?QF#4;W\8 M[9/Y$1K^?UKZ ^,GA6/7OA9>Q6L*B;2U%W;*H^Z(Q\RC_@&X8]<4#/F+P)XC M;PGXXTO6 Q$=O.!.!WB;Y7'_ 'R3CWQ7VXCK+&KQL&1@"K Y!![U\!U]=?!# MQ/\ \)'\-+..9]UUIA^QRYZX4?(?^^"!GU!H!G9ZIX>T?6FC?5M,M+QXAB-Y MH59D'< GD59L=/L]+LTM--M(+2W3[L,$81%^@'%6**!!1110 4444 %%%% ! M4%W]J^SDV!A\X=!,#M/MD=/UJ>B@35U8\YUGX@>(- N_L^IZ)!$6Y1Q(Q5QZ M@]ZSO^%O7_\ T"[?_OXU>CZUHUKKNE2V-ZF46LEC?3VD_ M$D$C1OCU!P:]+#QHU5K'5'RV95,9@YIQJ-Q?I_D=[_PMZ_\ ^@7;_P#?QJ4? M%Z^W#=I=N1W D85YW175]6I=CRO[4QG\_P"7^1ZS8?%O3YF"ZAI\]MG^*-A( M!_(_SKM-+UG3]9M_/TR[CN$[[3ROU!Y'XU\Y5:T[4KO2KU+O3YV@F0\,IZ^Q M'<>U8U,'!KW-#MP^>5H.U9M3_WU_P#0%KU[PIX@3Q)H M4=Z%"3 ^7,@Z*XZX]CD'\:\A\>_\CUJ?^^O_ * M882+C5:9WYU4C4PD)QV; M_1G.T445ZA\B%%%% !7I'P?_ ./O5?\ ;UZ1\'_P#C[U7_ '(_YM7/ MB?X+/3RK_?8?/\F_\CUJ?^^O_H"USM:TOXI5Y;\'_\ C[U7_+BOXS/N\G_P!RA\_S9\]_M.W^ZZ\/:=:,?XH6^[S MWQRI]U-7?A)XR_X0SQ]:W%Q)LT^[_P!&O,G@(QX?_@)P?IGUKVK]H3P<-:\' M)KUI'F\T@Y?:.7@8_-_WR<-[#=ZU\O4#/>?VC?&HFFM?"-A+E8B+F^*GJQ'[ MM/R.X_5?2O1/@QX.'A+X?VS3Q[;_ %("ZN+O#EQX2\67^BW8;=:RD(Y M'^LC/*-^*D&@2/A?$/[#= MR".WU:+[."QP!*#F/\^5'NPKZMH!A1110(\@_:1OUM_AW:6@;]Y=:@GR^JJC M$G\]OYU\OUZQ^T#XNC\0>-X]*LI!):Z.K1%E.0TS$>9^6%7ZJ:\^\+>'+WQ9 MXFL]&TY29KF0*6QD1K_$Y]@,F@H^H/@+IKZ?\);&20;6O)I;C!]"VT?F$!_& MN0_:?_Y!OAW_ *[3_P DKVW2].M](TFTTZR79;VD*0Q#T50 /Y5XE^T__P @ MWP[_ -=I_P"24"/G>OO?3_\ D&VW_7%/Y"O@BOO?3_\ D&VW_7%/Y"@&6*** M*!'@'[47_,K?]O?_ +1KY_KZ _:B_P"96_[>_P#VC7S_ $%(^_ZXWXN2+%\) M?$#-G!MMO'J64#^==E7!_&R4P_!O7F SE85_.>,?UH)/-/V8?^0EXB_ZXP?S M>OH9T62-DD4,C##*PR"/2OGG]F'_ )"7B+_KC!_-Z^AZ!L^6?C+\)F\(W;:Y MH,);1)W^>,W0]L^4([1R*\;%74Y5E."#ZU][W=I!?V0I/ M;SH8Y(G&5=2,$$5\E?%GX87'@+6?M%DKRZ'=N?L\IY\INOE,?4=CW'N#0"/5 M_A3\6D\5:%-H/B"94UJ"W812LW_'XH4\_P"^ .1WZ^N/._V=%!^*+D@$KI\I M&1T.Y*\L@GEMIXY[>1HI8V#(Z-AE(Z$$=#7JG[.?_)4)/^P=+_Z$E 'U/7F? MQX\5?\(]\.Y;*"3;=ZNQM4 /(CQF0_3'R_\ Z],KY+^-WB:3Q7\3);&R+2V M^FG[% B\[Y,_.0/4M\OOM% "_!?Q;X9\%:QJ&J^(Y)Q<-"(+410E\ G+D^AX M4?G7L3_M ^ W0H\UZRL,$&T)!%0:5^SUX/BTVS&J174]XL*?:"MR0KR8&[ ' M09S5V7X ^ I% 2PNHCGJEV_/YDT!H?+&KBQ76KT:0[O8>>_V9I%PQCR=N1ZX MQ7I7[/OBG^Q/'YTJ>3;:ZQ'Y6">!*N2A_'YE_P"!"K7QJ^%>E^"=+T[4_#J3 MBVEE:"Y$LF_#$90C\ _Z5Y)9W*?"FG:U;8"WD"NR@YV/T9?P8$?A6O02%%%% !1110 4444 %%%% !7S[X MM_Y'#5?^OI_YU]!5X!XS4)XTU0+_ ,_#'\^:[\%\;/G<^_@P]?T,2BBBO4/D M HHHH ],^#\S;]5A_AQ$X'H?F'^'Y5ROCW_D>M3_ -]?_0%KIO@__P ?>J_[ MD?\ -JYGQ[_R/6I_[Z_^@+7'#_>9>G^1[E=WRJE_B?ZG.T445V'AA1110 5Z M1\'_ /C[U7_;UZ1\'_ /C[U7__\CUJ?^^O_ * M<[6M+^''T.7%_P"\5/5_F%%%%6

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moh-20210930_htm.xml IDEA: XBRL DOCUMENT 0001179929 2021-01-01 2021-09-30 0001179929 2021-10-22 0001179929 2021-07-01 2021-09-30 0001179929 2020-07-01 2020-09-30 0001179929 2020-01-01 2020-09-30 0001179929 2021-09-30 0001179929 2020-12-31 0001179929 us-gaap:CommonStockMember 2020-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001179929 us-gaap:RetainedEarningsMember 2020-12-31 0001179929 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001179929 2021-01-01 2021-03-31 0001179929 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001179929 us-gaap:CommonStockMember 2021-03-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001179929 us-gaap:RetainedEarningsMember 2021-03-31 0001179929 2021-03-31 0001179929 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001179929 2021-04-01 2021-06-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001179929 us-gaap:CommonStockMember 2021-06-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001179929 us-gaap:RetainedEarningsMember 2021-06-30 0001179929 2021-06-30 0001179929 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001179929 us-gaap:CommonStockMember 2021-09-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001179929 us-gaap:RetainedEarningsMember 2021-09-30 0001179929 us-gaap:CommonStockMember 2019-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001179929 us-gaap:RetainedEarningsMember 2019-12-31 0001179929 2019-12-31 0001179929 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001179929 2020-01-01 2020-03-31 0001179929 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001179929 us-gaap:CommonStockMember 2020-03-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001179929 us-gaap:RetainedEarningsMember 2020-03-31 0001179929 2020-03-31 0001179929 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001179929 2020-04-01 2020-06-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001179929 us-gaap:CommonStockMember 2020-06-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001179929 us-gaap:RetainedEarningsMember 2020-06-30 0001179929 2020-06-30 0001179929 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001179929 us-gaap:CommonStockMember 2020-09-30 0001179929 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001179929 us-gaap:RetainedEarningsMember 2020-09-30 0001179929 2020-09-30 0001179929 moh:HealthPlansMember 2021-09-30 0001179929 srt:MinimumMember moh:HealthPlansMember 2021-01-01 2021-09-30 0001179929 srt:MaximumMember moh:HealthPlansMember 2021-01-01 2021-09-30 0001179929 moh:NewYorkAcquisitionMedicaidMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0001179929 stpr:NY moh:AgeWellNewYorkMember 2021-08-31 0001179929 stpr:NY moh:AgeWellNewYorkMember 2020-01-01 2020-12-31 0001179929 moh:NewYorkAcquisitionMedicaidMember us-gaap:SubsequentEventMember 2021-10-07 2021-10-07 0001179929 2021-09-01 2021-09-30 0001179929 moh:HidalgoTarrantAndNortheastServiceAreasMember moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember 2020-12-31 0001179929 moh:HidalgoServiceAreaMember moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember 2020-12-31 0001179929 moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember 2020-01-01 2020-12-31 0001179929 moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember 2021-04-22 2021-04-22 0001179929 moh:GovernmentReceivablesMember 2021-09-30 0001179929 moh:GovernmentReceivablesMember 2020-12-31 0001179929 moh:PharmacyRebateReceivablesMember 2021-09-30 0001179929 moh:PharmacyRebateReceivablesMember 2020-12-31 0001179929 moh:HealthInsurerFeeReimbursementReceivablesMember 2021-09-30 0001179929 moh:HealthInsurerFeeReimbursementReceivablesMember 2020-12-31 0001179929 moh:OtherReceivablesMember 2021-09-30 0001179929 moh:OtherReceivablesMember 2020-12-31 0001179929 moh:CompleteCareReceivablesMember 2021-09-30 0001179929 moh:CompleteCareReceivablesMember 2020-12-31 0001179929 moh:COVID19Member 2021-07-01 2021-09-30 0001179929 moh:COVID19Member 2021-01-01 2021-09-30 0001179929 moh:StructuredSecuritiesMember 2021-01-01 2021-09-30 0001179929 moh:MagellanCompleteCareMember 2020-12-31 0001179929 moh:MagellanCompleteCareMember 2020-12-31 2020-12-31 0001179929 moh:MagellanCompleteCareMember 2021-01-01 2021-09-30 0001179929 us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001179929 us-gaap:CommercialMortgageBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:USTreasuryNotesSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryNotesSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryNotesSecuritiesMember 2021-09-30 0001179929 us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001179929 moh:MunicipalSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member moh:MunicipalSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member moh:MunicipalSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member moh:MunicipalSecuritiesMember 2021-09-30 0001179929 moh:OtherSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member moh:OtherSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member moh:OtherSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member moh:OtherSecuritiesMember 2021-09-30 0001179929 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001179929 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001179929 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001179929 moh:PassportHealthPlanIncMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001179929 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001179929 us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001179929 us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001179929 moh:MunicipalSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member moh:MunicipalSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member moh:MunicipalSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member moh:MunicipalSecuritiesMember 2020-12-31 0001179929 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001179929 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001179929 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001179929 moh:PassportHealthPlanIncMember 2021-09-30 0001179929 moh:A4375SeniorNotesMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:A4375SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:A4375SeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:A4375SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:A4375SeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:SeniorNotesDue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:SeniorNotesDue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:SeniorNotesDue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001179929 moh:MagellanCompleteCareMember 2021-09-30 0001179929 moh:MedicaidMember 2020-12-31 0001179929 moh:MedicareMember 2020-12-31 0001179929 moh:MarketplaceMember 2020-12-31 0001179929 moh:MedicaidMember 2021-01-01 2021-09-30 0001179929 moh:MedicareMember 2021-01-01 2021-09-30 0001179929 moh:MarketplaceMember 2021-01-01 2021-09-30 0001179929 moh:MedicaidMember 2021-09-30 0001179929 moh:MedicareMember 2021-09-30 0001179929 moh:MarketplaceMember 2021-09-30 0001179929 moh:MedicaidMember 2019-12-31 0001179929 moh:MedicareMember 2019-12-31 0001179929 moh:MarketplaceMember 2019-12-31 0001179929 moh:MedicaidMember 2020-01-01 2020-09-30 0001179929 moh:MedicareMember 2020-01-01 2020-09-30 0001179929 moh:MarketplaceMember 2020-01-01 2020-09-30 0001179929 moh:MedicaidMember 2020-09-30 0001179929 moh:MedicareMember 2020-09-30 0001179929 moh:MarketplaceMember 2020-09-30 0001179929 moh:A4375SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2020-12-31 0001179929 moh:ThreePointEightSevenFivePercentSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001179929 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-30 0001179929 us-gaap:LineOfCreditMember 2021-01-01 2021-09-30 0001179929 us-gaap:CommonStockMember 2021-01-01 2021-01-31 0001179929 us-gaap:CommonStockMember 2021-02-01 2021-02-28 0001179929 us-gaap:CommonStockMember 2021-01-01 2021-02-28 0001179929 us-gaap:CommonStockMember 2020-11-01 2020-12-31 0001179929 us-gaap:CommonStockMember 2020-12-01 2020-12-31 0001179929 moh:HealthPlansMember 2021-07-01 2021-09-30 0001179929 moh:HealthPlansMember 2020-07-01 2020-09-30 0001179929 moh:HealthPlansMember 2021-01-01 2021-09-30 0001179929 moh:HealthPlansMember 2020-01-01 2020-09-30 0001179929 moh:MedicareMember 2021-07-01 2021-09-30 0001179929 moh:MedicareMember 2020-07-01 2020-09-30 0001179929 moh:MarketplaceMember 2021-07-01 2021-09-30 0001179929 moh:MarketplaceMember 2020-07-01 2020-09-30 0001179929 us-gaap:AllOtherSegmentsMember 2021-07-01 2021-09-30 0001179929 us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0001179929 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-09-30 0001179929 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0001179929 moh:HealthPlansMember 2020-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2021-09-30 0001179929 us-gaap:AllOtherSegmentsMember 2020-12-31 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2021-07-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2020-07-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2021-01-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2020-01-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MedicareMember 2021-07-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MedicareMember 2020-07-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MedicareMember 2021-01-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MedicareMember 2020-01-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MarketplaceMember 2021-07-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MarketplaceMember 2020-07-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MarketplaceMember 2021-01-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember moh:MarketplaceMember 2020-01-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-07-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0001179929 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0001179929 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0001179929 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0001179929 us-gaap:MaterialReconcilingItemsMember 2020-07-01 2020-09-30 0001179929 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 0001179929 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-09-30 shares iso4217:USD iso4217:USD shares moh:member moh:position pure 0001179929 --12-31 2021 Q3 false P3Y 10-Q true 2021-09-30 false 001-31719 MOLINA HEALTHCARE, INC. DE 13-4204626 200 Oceangate Suite 100 Long Beach, CA 90802 562 435-3666 Common Stock, $0.001 Par Value MOH NYSE Yes Yes Large Accelerated Filer false false false 58400000 6800000000 4768000000 19689000000 13444000000 204000000 170000000 576000000 477000000 0 69000000 0 206000000 20000000 10000000 39000000 48000000 16000000 4000000 58000000 13000000 7040000000 5021000000 20362000000 14188000000 6049000000 4098000000 17342000000 11412000000 532000000 368000000 1489000000 1030000000 204000000 170000000 576000000 477000000 0 70000000 0 209000000 32000000 23000000 96000000 64000000 2000000 3000000 30000000 9000000 6819000000 4732000000 19533000000 13201000000 221000000 289000000 829000000 987000000 30000000 27000000 90000000 72000000 0 0 0 -5000000 -30000000 -27000000 -90000000 -77000000 191000000 262000000 739000000 910000000 48000000 77000000 183000000 271000000 143000000 185000000 556000000 639000000 2.49 3.14 9.63 10.80 2.46 3.10 9.51 10.65 143000000 185000000 556000000 639000000 -13000000 6000000 -27000000 43000000 -4000000 1000000 -7000000 10000000 -9000000 5000000 -20000000 33000000 134000000 190000000 536000000 672000000 4357000000 4154000000 2900000000 1875000000 1912000000 1672000000 197000000 175000000 9366000000 7876000000 385000000 391000000 915000000 941000000 156000000 136000000 83000000 69000000 128000000 119000000 11033000000 9532000000 3191000000 2696000000 2081000000 1253000000 797000000 641000000 1000000 375000000 6070000000 4965000000 2130000000 2127000000 220000000 225000000 95000000 119000000 8515000000 7436000000 0.001 0.001 150000000 150000000 58000000 59000000 0 0 0.001 0.001 20000000 20000000 0 0 0 0 0 0 205000000 199000000 17000000 37000000 2296000000 1860000000 2518000000 2096000000 11033000000 9532000000 59000000 0 199000000 37000000 1860000000 2096000000 228000000 228000000 1000000 2000000 120000000 122000000 -11000000 -11000000 -27000000 -27000000 58000000 0 170000000 26000000 1968000000 2164000000 185000000 185000000 21000000 21000000 58000000 0 191000000 26000000 2153000000 2370000000 143000000 143000000 -9000000 -9000000 14000000 14000000 58000000 0 205000000 17000000 2296000000 2518000000 62000000 0 175000000 4000000 1781000000 1960000000 178000000 178000000 3000000 9000000 437000000 446000000 -30000000 -30000000 -19000000 -19000000 4000000 4000000 59000000 0 140000000 -15000000 1522000000 1647000000 276000000 276000000 47000000 47000000 26000000 26000000 59000000 0 166000000 32000000 1798000000 1996000000 185000000 185000000 5000000 5000000 15000000 15000000 59000000 0 181000000 37000000 1983000000 2201000000 556000000 639000000 96000000 64000000 8000000 3000000 49000000 43000000 0 -5000000 9000000 2000000 247000000 369000000 43000000 98000000 522000000 431000000 810000000 -24000000 129000000 63000000 -374000000 -188000000 23000000 34000000 1522000000 599000000 2018000000 670000000 965000000 891000000 56000000 64000000 0 62000000 -3000000 -3000000 -1106000000 98000000 128000000 453000000 52000000 8000000 20000000 0 0 789000000 0 600000000 0 380000000 -4000000 -47000000 -204000000 61000000 212000000 758000000 4223000000 2508000000 4435000000 3266000000 Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. For further information, refer to Note 10, “Segments.”</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we served approximately 4.8 million members eligible for government-sponsored healthcare programs, located across 18 states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0MzdlNzcxMDk2NTQwM2FhNmQwNGE0MTY1YTJhNjJhL3NlYzo4NDM3ZTc3MTA5NjU0MDNhYTZkMDRhNDE2NWEyYTYyYV8zMS9mcmFnOjkxNmZlMDc2ZWI5YjQxZWY5YjcwY2ZjM2M1NjY1NWJhL3RleHRyZWdpb246OTE2ZmUwNzZlYjliNDFlZjliNzBjZmMzYzU2NjU1YmFfNzMy_69377d3e-95cc-4d63-b671-b36d17037fce">three</span> to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFPs”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (“ABD”); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition—Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition—Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement—Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, we announced that our Nevada health plan subsidiary was selected as an awardee in Clark and Washoe Counties. This new contract is expected to commence on January 1, 2022, and will offer health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two year extension was ratified in September 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement—Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The state currently expects a final RFP to be released in February 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition—Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio Procurement—Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin July 1, 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results for the entire year ending December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, 2020, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets; and</span></div>•The determination of unrecognized tax benefits. 4800000 18 P5Y 380000000 13000 700000000 110000000 P4Y P2Y 48000 2000 1000000000 60000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results for the entire year ending December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, 2020, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets; and</span></div>•The determination of unrecognized tax benefits. Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable. Our adjustment is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September 30, 2021, Marketplace risk adjustment payables amounted to $691 million and related receivables amounted to $29 million, for a net payable of $662 million, of which $660 million related to 2021, and $2 million related primarily to 2020. As of December 31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div>Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table> The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table> 4357000000 3196000000 78000000 70000000 4435000000 3266000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table> 1331000000 969000000 264000000 178000000 25000000 104000000 292000000 255000000 0 166000000 1912000000 1672000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”</span></div>Contractual Provisions That May Adjust or Limit Revenue or ProfitMany of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions.<div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable. Our adjustment is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace</span></div>Risk Adjustment. Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table> 852000000 513000000 249000000 76000000 87000000 45000000 82000000 62000000 41000000 30000000 691000000 326000000 30000000 37000000 49000000 21000000 0 143000000 2081000000 1253000000 -17000000 -183000000 691000000 29000000 662000000 -660000000 -2000000 326000000 20000000 306000000 <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div> P10Y P10Y <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div> Recent Accounting PronouncementsVarious recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements Net Income per Share <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.51 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.65 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Source data for calculations in thousands.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.51 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.65 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Source data for calculations in thousands.</span></div> 143000000 185000000 556000000 639000000 57800000 58700000 58000000.0 61900000 0 0 500000 2800000 0 0 300000 100000 57800000 58700000 57800000 59200000 700000 900000 700000 800000 58500000 59600000 58500000 60000000.0 2.49 3.14 9.63 10.80 2.46 3.10 9.51 10.65 Business Combinations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, we closed on our acquisition of 100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $1,037 million. In the nine months ended September 30, 2021, we recorded various measurement period adjustments, including a decrease of $7 million to “Receivables,” a decrease of $27 million to “Medical claims and benefits payable,” and an increase of $18 million to “Amounts due government agencies.” In the aggregate, we recorded a net increase of $9 million to goodwill for these measurement period adjustments and various purchase price adjustments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, “Segments” for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.</span></div> 1 1037000000 7000000 27000000 18000000 9000000 Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, “Fair Value Measurements.”</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in “Other” operating expenses in our consolidated statements of income. In the nine months ended September 30, 2021, we recognized a loss of $3 million for the increase in the fair value of the contingent consideration liabilities described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $26 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23 million, was paid to the seller. The portion of the contingent purchase consideration paid in the first quarter of 2021 has been presented primarily in “Financing activities” in the accompanying consolidated statements of cash flows for the nine months ended September 30, 2021, with the balance reflected in “Operating activities.” We expect to pay the remaining balance of the liabilities, reported in “Accounts payable, accrued liabilities and other” in the accompanying consolidated balance sheets, by the end of the first quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements – Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div> 1705000000 0 1705000000 0 610000000 0 610000000 0 235000000 0 235000000 0 224000000 0 224000000 0 97000000 0 97000000 0 29000000 0 29000000 0 2900000000 0 2900000000 0 26000000 0 0 26000000 26000000 0 0 26000000 1256000000 0 1256000000 0 392000000 0 392000000 0 27000000 0 27000000 0 132000000 0 132000000 0 68000000 0 68000000 0 1875000000 0 1875000000 0 46000000 0 0 46000000 46000000 0 0 46000000 -3000000 26000000 23000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table> 0.04375 790000000 835000000 789000000 843000000 0.05375 698000000 725000000 697000000 742000000 0.03875 642000000 688000000 641000000 691000000 2130000000 2248000000 2127000000 2276000000 Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of September 30, 2021 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to $6 million and $7 million for the three and nine months ended September 30, 2021, respectively. Gross realized investment gains were insignificant for three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at September 30, 2021, and December 31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of September 30, 2021, and December 31, 2020.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $156 million at September 30, 2021, of which $148 million will mature in one year or less, and $8 million will mature after one through five years.</span></div> The following tables summarize our investments as of the dates indicated:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div> 1688000000 19000000 2000000 1705000000 607000000 4000000 1000000 610000000 235000000 0 0 235000000 223000000 1000000 0 224000000 96000000 1000000 0 97000000 29000000 0 0 29000000 2878000000 25000000 3000000 2900000000 1220000000 36000000 0 1256000000 383000000 10000000 1000000 392000000 27000000 0 0 27000000 130000000 2000000 0 132000000 66000000 2000000 0 68000000 1826000000 50000000 1000000 1875000000 <div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of September 30, 2021 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 555000000 557000000 1530000000 1546000000 296000000 298000000 497000000 499000000 2878000000 2900000000 6000000 7000000 6000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of September 30, 2021, and December 31, 2020.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div> 509000000 2000000 2000000 174 0 0 0 270000000 1000000 1000000 94 77000000 1000000 21 779000000 3000000 3000000 268 77000000 1000000 21 156000000 148000000 8000000 Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Other” medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $301 million and $235 million as of September 30, 2021, and December 31, 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for “Components of medical care costs related to: Prior years” represent decreases in medical care costs resulting from actual medical care costs being less than we previously estimated in the prior year.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in acquired balances </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $216 million and $66 million as of September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior period development recognized in the nine months ended September 30, 2021 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our previous estimates in 2020.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 2246000000 1647000000 209000000 157000000 86000000 70000000 650000000 528000000 0 294000000 3191000000 2696000000 301000000 235000000 The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for “Components of medical care costs related to: Prior years” represent decreases in medical care costs resulting from actual medical care costs being less than we previously estimated in the prior year.<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in acquired balances </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 2129000000 392000000 175000000 2696000000 13491000000 2195000000 1872000000 17558000000 -158000000 -36000000 -22000000 -216000000 13333000000 2159000000 1850000000 17342000000 11530000000 1816000000 1534000000 14880000000 1538000000 340000000 130000000 2008000000 13068000000 2156000000 1664000000 16888000000 -19000000 -8000000 0 -27000000 68000000 0 0 68000000 2443000000 387000000 361000000 3191000000 1465000000 267000000 122000000 1854000000 9029000000 1588000000 861000000 11478000000 -41000000 -25000000 0 -66000000 8988000000 1563000000 861000000 11412000000 7470000000 1316000000 714000000 9500000000 1193000000 233000000 101000000 1527000000 8663000000 1549000000 815000000 11027000000 50000000 0 0 50000000 1840000000 281000000 168000000 2289000000 -216000000 -66000000 Debt <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-term debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (“Credit Agreement”) which includes a revolving credit facility (“Credit Facility”) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of September 30, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September 30, 2021, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High-Yield Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contains customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $800 million aggregate principal amount of senior notes (the “4.375% Notes”) outstanding as of September 30, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.375% Notes due 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $700 million aggregate principal amount of senior notes (the “5.375% Notes”) outstanding as of September 30, 2021, which are due November 15, 2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.875% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $650 million aggregate principal amount of senior notes (the “3.875% Notes”) outstanding as of September 30, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div> The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table> 0.04375 800000000 800000000 0.05375 700000000 700000000 0.03875 650000000 650000000 20000000 23000000 2130000000 2127000000 1000000000 P5Y 0 0.04375 800000000 0.04375 0.04375 0.05375 700000000 0.05375 0.05375 0.03875 650000000 0.03875 0.03875 Stockholders' Equity <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program immediately supersedes the stock purchase program previously approved by our board of directors in September 2020. This new program will be funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of October 28, 2021, no shares had been purchased under the stock purchase program approved in 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading </span></div>plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In November and December 2020, we purchased 766,000 shares of our common stock for $159 million (average cost of $208.37), including approximately 29,000 shares purchased for $6 million in late December 2020, and settled in early January 2021. 500000000 500000000 577000 122000000 211.65 766000 159000000 208.37 29000 6000000 Segments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (“MCR”). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,040 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,362 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles assets, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,358 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,040 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,362 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles assets, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,358 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.</span></div> 5354000000 3996000000 15583000000 11124000000 875000000 636000000 2502000000 1909000000 793000000 389000000 2224000000 1155000000 18000000 0 53000000 0 7040000000 5021000000 20362000000 14188000000 387000000 378000000 247000000 247000000 67000000 67000000 135000000 157000000 65000000 76000000 14000000 16000000 915000000 941000000 532000000 509000000 1687000000 1427000000 151000000 91000000 329000000 333000000 68000000 70000000 331000000 272000000 4000000 0 11000000 0 755000000 670000000 2358000000 2032000000 222000000 253000000 620000000 744000000 756000000 634000000 2149000000 1789000000 221000000 289000000 829000000 987000000 -30000000 -27000000 -90000000 -77000000 191000000 262000000 739000000 910000000 Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. The consequences associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the Court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare of Kentucky and Anthem. The new Medicaid contracts commenced on January 1, 2021. On April 28, 2021, the Court issued its preliminary Opinion and Order, which Opinion and Order the Court finalized on June 16, 2021. Under the final Order, which the Court indicated is immediately appealable by the parties, the Court, among other things, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina’s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the Court ordered a new RFP, with the status quo of six health plans serving Kentucky Medicaid members to continue in the interim. On July 15-16, 2021, each of United, Molina, Humana, and Aetna filed notices of appeal. On July 23, 2021, both the Kentucky Finance and Administration Cabinet and the Kentucky Cabinet for Health and Family Services filed notices of cross appeal, and on July 26, 2021, Anthem filed a notice of cross appeal. This matter remains subject to potential additional legal and appellate proceedings, and no assurances can be given regarding the ultimate outcome. Under the Court’s June 16, 2021 final Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto, Inc. (MHPR) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (ASES). On September 13, 2021, in addition to filing its answer to MHPR’s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers and, in addition to damages, seeks various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations. This matter is in its early stages, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR’s complaint or the counterclaim of ASES.</span></div> XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
shares in Millions
9 Months Ended
Sep. 30, 2021
Oct. 22, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-31719  
Entity Registrant Name MOLINA HEALTHCARE, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 13-4204626  
Entity Address, Address Line One 200 Oceangate  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Long Beach,  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90802  
City Area Code 562  
Local Phone Number 435-3666  
Title of 12(b) Security Common Stock, $0.001 Par Value  
Trading Symbol MOH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   58.4
Entity Central Index Key 0001179929  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Amendment Flag false  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Premium revenue $ 6,800 $ 4,768 $ 19,689 $ 13,444
Premium tax revenue 204 170 576 477
Health insurer fees reimbursed 0 69 0 206
Investment income 20 10 39 48
Other revenue 16 4 58 13
Total revenue 7,040 5,021 20,362 14,188
Operating expenses:        
Medical care costs 6,049 4,098 17,342 11,412
General and administrative expenses 532 368 1,489 1,030
Premium tax expenses 204 170 576 477
Health insurer fees 0 70 0 209
Depreciation and amortization 32 23 96 64
Other 2 3 30 9
Total operating expenses 6,819 4,732 19,533 13,201
Operating income 221 289 829 987
Other expenses, net:        
Interest expense 30 27 90 72
Other expense, net 0 0 0 5
Total other expenses, net 30 27 90 77
Income before income tax expense 191 262 739 910
Income tax expense 48 77 183 271
Net income $ 143 $ 185 $ 556 $ 639
Net income per share:        
Net income per share - Basic (in dollars per share) $ 2.49 $ 3.14 $ 9.63 $ 10.80
Net income per share - Diluted (in dollars per share) $ 2.46 $ 3.10 $ 9.51 $ 10.65
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net income $ 143 $ 185 $ 556 $ 639
Other comprehensive loss income:        
Unrealized investment (loss) income (13) 6 (27) 43
Less: effect of income taxes (4) 1 (7) 10
Other comprehensive (loss) income, net of tax (9) 5 (20) 33
Comprehensive income $ 134 $ 190 $ 536 $ 672
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 4,357 $ 4,154
Investments 2,900 1,875
Receivables 1,912 1,672
Prepaid expenses and other current assets 197 175
Total current assets 9,366 7,876
Property, equipment, and capitalized software, net 385 391
Goodwill, and intangible assets, net 915 941
Restricted investments 156 136
Deferred income taxes 83 69
Other assets 128 119
Total assets 11,033 9,532
Current liabilities:    
Medical claims and benefits payable 3,191 2,696
Amounts due government agencies 2,081 1,253
Accounts payable, accrued liabilities and other 797 641
Deferred revenue 1 375
Total current liabilities 6,070 4,965
Long-term debt 2,130 2,127
Finance lease liabilities 220 225
Other long-term liabilities 95 119
Total liabilities 8,515 7,436
Stockholders’ equity:    
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2021, and 59 million shares at December 31, 2020 0 0
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding 0 0
Additional paid-in capital 205 199
Accumulated other comprehensive income 17 37
Retained earnings 2,296 1,860
Total stockholders’ equity 2,518 2,096
Total liabilities and stockholders’ equity $ 11,033 $ 9,532
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares outstanding (in shares) 58,000,000 59,000,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Retained Earnings
Beginning Balance (in shares) at Dec. 31, 2019 61.9 62.0      
Beginning Balance at Dec. 31, 2019 $ 1,960 $ 0 $ 175 $ 4 $ 1,781
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 178       178
Common stock purchases (in shares)   (3.0)      
Common stock purchases (446)   (9)   (437)
Termination of warrants (30)   (30)    
Other comprehensive income (loss), net (19)     (19)  
Share-based compensation 4   4    
Ending Balance (in shares) at Mar. 31, 2020   59.0      
Ending Balance at Mar. 31, 2020 $ 1,647 $ 0 140 (15) 1,522
Beginning Balance (in shares) at Dec. 31, 2019 61.9 62.0      
Beginning Balance at Dec. 31, 2019 $ 1,960 $ 0 175 4 1,781
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 639        
Other comprehensive income (loss), net 33        
Ending Balance (in shares) at Sep. 30, 2020   59.0      
Ending Balance at Sep. 30, 2020 2,201 $ 0 181 37 1,983
Beginning Balance (in shares) at Mar. 31, 2020   59.0      
Beginning Balance at Mar. 31, 2020 1,647 $ 0 140 (15) 1,522
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 276       276
Other comprehensive income (loss), net 47     47  
Share-based compensation $ 26   26    
Ending Balance (in shares) at Jun. 30, 2020 58.7 59.0      
Ending Balance at Jun. 30, 2020 $ 1,996 $ 0 166 32 1,798
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 185       185
Other comprehensive income (loss), net 5     5  
Share-based compensation 15   15    
Ending Balance (in shares) at Sep. 30, 2020   59.0      
Ending Balance at Sep. 30, 2020 $ 2,201 $ 0 181 37 1,983
Beginning Balance (in shares) at Dec. 31, 2020 58.0 59.0      
Beginning Balance at Dec. 31, 2020 $ 2,096 $ 0 199 37 1,860
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 228       228
Common stock purchases (in shares)   (1.0)      
Common stock purchases (122)   (2)   (120)
Other comprehensive income (loss), net (11)     (11)  
Share-based compensation (27)   (27)    
Ending Balance (in shares) at Mar. 31, 2021   58.0      
Ending Balance at Mar. 31, 2021 $ 2,164 $ 0 170 26 1,968
Beginning Balance (in shares) at Dec. 31, 2020 58.0 59.0      
Beginning Balance at Dec. 31, 2020 $ 2,096 $ 0 199 37 1,860
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 556        
Other comprehensive income (loss), net (20)        
Ending Balance (in shares) at Sep. 30, 2021   58.0      
Ending Balance at Sep. 30, 2021 2,518 $ 0 205 17 2,296
Beginning Balance (in shares) at Mar. 31, 2021   58.0      
Beginning Balance at Mar. 31, 2021 2,164 $ 0 170 26 1,968
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 185       185
Share-based compensation $ 21   21    
Ending Balance (in shares) at Jun. 30, 2021 57.8 58.0      
Ending Balance at Jun. 30, 2021 $ 2,370 $ 0 191 26 2,153
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 143       143
Other comprehensive income (loss), net (9)     (9)  
Share-based compensation 14   14    
Ending Balance (in shares) at Sep. 30, 2021   58.0      
Ending Balance at Sep. 30, 2021 $ 2,518 $ 0 $ 205 $ 17 $ 2,296
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating activities:    
Net income $ 556 $ 639
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 96 64
Deferred income taxes (8) (3)
Share-based compensation 49 43
Loss on debt repayment 0 5
Other, net 9 2
Changes in operating assets and liabilities:    
Receivables (247) (369)
Prepaid expenses and other current assets (43) (98)
Medical claims and benefits payable 522 431
Amounts due government agencies 810 (24)
Accounts payable, accrued liabilities and other 129 63
Deferred revenue (374) (188)
Income taxes 23 34
Net cash provided by operating activities 1,522 599
Investing activities:    
Purchases of investments (2,018) (670)
Proceeds from sales and maturities of investments 965 891
Purchases of property, equipment and capitalized software (56) (64)
Net cash paid in business combinations 0 (62)
Other, net 3 3
Net cash (used in) provided by investing activities (1,106) 98
Financing activities:    
Common stock purchases (128) (453)
Common stock withheld to settle employee tax obligations (52) (8)
Contingent consideration liabilities settled (20) 0
Proceeds from senior notes offering, net of issuance costs 0 789
Repayment of term loan facility 0 (600)
Proceeds from borrowings under term loan facility 0 380
Other, net (4) (47)
Net cash (used in) provided by financing activities (204) 61
Net increase in cash, cash equivalents, and restricted cash and cash equivalents 212 758
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period 4,223 2,508
Cash, cash equivalents, and restricted cash and cash equivalents at end of period $ 4,435 $ 3,266
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Basis of Presentation
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation Organization and Basis of Presentation
Organization and Operations
Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. For further information, refer to Note 10, “Segments.”
As of September 30, 2021, we served approximately 4.8 million members eligible for government-sponsored healthcare programs, located across 18 states.
Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFPs”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.
In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (“ABD”); and regions or service areas.
Recent Developments
New York Acquisition—Medicaid. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.
New York Acquisition—Medicaid. On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.
Nevada Procurement—Medicaid. On August 17, 2021, we announced that our Nevada health plan subsidiary was selected as an awardee in Clark and Washoe Counties. This new contract is expected to commence on January 1, 2022, and will offer health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two year extension was ratified in September 2021.
California Procurement—Medicaid. The state currently expects a final RFP to be released in February 2022.
Texas Acquisition—Medicaid and Medicare. On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.
Ohio Procurement—Medicaid. On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin July 1, 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs.
Consolidation and Interim Financial Information
The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results for the entire year ending December 31, 2021.
The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, 2020, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, 2020.
Reclassifications
Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.
Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:
The determination of medical claims and benefits payable;
Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;
Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;
Settlements under risk- or savings-sharing programs;
Purchase price allocations relating to business combinations, including the determination of contingent consideration;
The assessment of long-lived and intangible assets, and goodwill for impairment;
The determination of reserves for potential absorption of claims unpaid by insolvent providers;
The determination of reserves for the outcome of litigation;
The determination of valuation allowances for deferred tax assets; and
•The determination of unrecognized tax benefits.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.
September 30,
 20212020
(In millions)
Cash and cash equivalents$4,357 $3,196 
Restricted cash and cash equivalents78 70 
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$4,435 $3,266 
Receivables
Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.
September 30,
2021
December 31,
2020
(In millions)
Government receivables$1,331 $969 
Pharmacy rebate receivables264 178 
Health insurer fee reimbursement receivables25 104 
Other292 255 
Magellan Complete Care acquisition opening balance — 166 
Total$1,912 $1,672 
Premium Revenue Recognition and Amounts Due Government Agencies
Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.
Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”
Contractual Provisions That May Adjust or Limit Revenue or Profit
Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:
September 30,
2021
December 31,
2020
(In millions)
Medicaid:
Minimum MLR and profit sharing$852 $513 
Other249 76 
Medicare:
Risk adjustment and Part D risk sharing87 45 
Minimum MLR and profit sharing 82 62 
Other41 30 
Marketplace:
Risk adjustment691 326 
Minimum MLR30 37 
Other49 21 
Magellan Complete Care acquisition opening balance— 143 
Total amounts due government agencies$2,081 $1,253 
Medicaid
Minimum MLR and Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable. Our adjustment is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.
Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.
It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Marketplace
Risk Adjustment. Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September 30, 2021, Marketplace risk adjustment payables amounted to $691 million and related receivables amounted to $29 million, for a net payable of $662 million, of which $660 million related to 2021, and $2 million related primarily to 2020. As of December 31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306 million.
Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.
Income Taxes
The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.
The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.
Recent Accounting Pronouncements
Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Income per Share Net Income per Share
The following table sets forth the calculation of net income per share:
Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
 (In millions, except net income per share)
Numerator:
Net income$143 $185 $556 $639 
Denominator:
Shares outstanding at the beginning of the period57.8 58.7 58.0 61.9 
Weighted-average number of shares issued:
Stock purchases— — (0.5)(2.8)
Stock-based compensation— — 0.3 0.1 
Denominator for basic net income per share57.8 58.7 57.8 59.2 
Effect of dilutive securities: (1)
Stock-based compensation0.7 0.9 0.7 0.8 
Denominator for diluted net income per share58.5 59.6 58.5 60.0 
Net income per share - Basic (2)
$2.49 $3.14 $9.63 $10.80 
Net income per share - Diluted (2)
$2.46 $3.10 $9.51 $10.65 
______________________________
(1)    The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.
(2)    Source data for calculations in thousands.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combinations
9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
On December 31, 2020, we closed on our acquisition of 100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $1,037 million. In the nine months ended September 30, 2021, we recorded various measurement period adjustments, including a decrease of $7 million to “Receivables,” a decrease of $27 million to “Medical claims and benefits payable,” and an increase of $18 million to “Amounts due government agencies.” In the aggregate, we recorded a net increase of $9 million to goodwill for these measurement period adjustments and various purchase price adjustments.
Refer to Note 10, “Segments” for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, “Fair Value Measurements.”
Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1) (Level 2) (Level 3)
 (In millions)
Corporate debt securities$1,705 $— $1,705 $— 
Mortgage-backed securities610 — 610 — 
U.S. Treasury notes235 — 235 — 
Asset-backed securities224 — 224 — 
Municipal securities97 — 97 — 
Other
29 — 29 — 
Total assets$2,900 $— $2,900 $— 
Contingent consideration liabilities$26 $— $— $26 
Total liabilities$26 $— $— $26 
Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1)(Level 2)(Level 3)
 (In millions)
Corporate debt securities$1,256 $— $1,256 $— 
Mortgage-backed securities392 — 392 — 
U.S. Treasury notes27 — 27 — 
Asset-backed securities132 — 132 — 
Municipal securities68 — 68 — 
Total assets $1,875 $— $1,875 $— 
Contingent consideration liabilities $46 $— $— $46 
Total liabilities$46 $— $— $46 
The net changes in fair value of Level 3 financial instruments are reported in “Other” operating expenses in our consolidated statements of income. In the nine months ended September 30, 2021, we recognized a loss of $3 million for the increase in the fair value of the contingent consideration liabilities described below.
Contingent Consideration Liabilities
As of September 30, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $26 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23 million, was paid to the seller. The portion of the contingent purchase consideration paid in the first quarter of 2021 has been presented primarily in “Financing activities” in the accompanying consolidated statements of cash flows for the nine months ended September 30, 2021, with the balance reflected in “Operating activities.” We expect to pay the remaining balance of the liabilities, reported in “Accounts payable, accrued liabilities and other” in the accompanying consolidated balance sheets, by the end of the first quarter of 2022.
Fair Value Measurements – Disclosure Only
The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.
 September 30, 2021December 31, 2020
 Carrying
Amount
Fair Value Carrying
Amount
Fair Value
 (In millions)
4.375% Notes
$790 $835 $789 $843 
5.375% Notes
698 725 697 742 
3.875% Notes
642 688 641 691 
Total$2,130 $2,248 $2,127 $2,276 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Investments
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for-Sale
We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:
 September 30, 2021
Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,688 $19 $$1,705 
Mortgage-backed securities607 610 
U.S. Treasury notes
235 — — 235 
Asset-backed securities223 — 224 
Municipal securities96 — 97 
Other29 — — 29 
Total$2,878 $25 $$2,900 

 December 31, 2020
 Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,220 $36 $— $1,256 
Mortgage-backed securities383 10 392 
U.S. Treasury notes
27 — — 27 
Asset-backed securities130 — 132 
Municipal securities66 — 68 
Total$1,826 $50 $$1,875 
The contractual maturities of our available-for-sale investments as of September 30, 2021 are summarized below:
Amortized CostEstimated
Fair Value
 (In millions)
Due in one year or less$555 $557 
Due after one year through five years1,530 1,546 
Due after five years through ten years296 298 
Due after ten years497 499 
Total$2,878 $2,900 
Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to $6 million and $7 million for the three and nine months ended September 30, 2021, respectively. Gross realized investment gains were insignificant for three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2021, and 2020.
We have determined that unrealized losses at September 30, 2021, and December 31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.
The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of September 30, 2021, and December 31, 2020.
 September 30, 2021December 31, 2020
 Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
 (Dollars in millions)
Corporate debt securities$509 $174 $— $— — 
Mortgage-backed securities
270 94 77 21 
Total$779 $268 $77 $21 
Held-to-Maturity
Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.
We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $156 million at September 30, 2021, of which $148 million will mature in one year or less, and $8 million will mature after one through five years.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Medical Claims and Benefits Payable
9 Months Ended
Sep. 30, 2021
Other Liabilities Disclosure [Abstract]  
Medical Claims and Benefits Payable Medical Claims and Benefits Payable
The following table provides the details of our medical claims and benefits payable as of the dates indicated:
September 30,
2021
December 31,
2020
 (In millions)
Fee-for-service claims incurred but not paid (“IBNP”)$2,246 $1,647 
Pharmacy payable209 157 
Capitation payable86 70 
Other650 528 
Magellan Complete Care acquisition opening balance— 294 
Total$3,191 $2,696 
“Other” medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $301 million and $235 million as of September 30, 2021, and December 31, 2020, respectively.
The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for “Components of medical care costs related to: Prior years” represent decreases in medical care costs resulting from actual medical care costs being less than we previously estimated in the prior year.
Nine Months Ended September 30, 2021
Medicaid Medicare MarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$2,129 $392 $175 $2,696 
Components of medical care costs related to:
Current year13,491 2,195 1,872 17,558 
Prior years(158)(36)(22)(216)
Total medical care costs13,333 2,159 1,850 17,342 
Payments for medical care costs related to:
Current year11,530 1,816 1,534 14,880 
Prior years1,538 340 130 2,008 
Total paid13,068 2,156 1,664 16,888 
Change in acquired balances (19)(8)— (27)
Change in non-risk and other provider payables68 — — 68 
Medical claims and benefits payable, ending balance$2,443 $387 $361 $3,191 

Nine Months Ended September 30, 2020
Medicaid MedicareMarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$1,465 $267 $122 $1,854 
Components of medical care costs related to:
Current year9,029 1,588 861 11,478 
Prior years(41)(25)— (66)
Total medical care costs8,988 1,563 861 11,412 
Payments for medical care costs related to:
Current year7,470 1,316 714 9,500 
Prior years1,193 233 101 1,527 
Total paid8,663 1,549 815 11,027 
Change in non-risk and other provider payables50 — — 50 
Medical claims and benefits payable, ending balance$1,840 $281 $168 $2,289 
Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $216 million and $66 million as of September 30, 2021, and 2020, respectively.
The favorable prior period development recognized in the nine months ended September 30, 2021 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our previous estimates in 2020.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt Debt
All long-term debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:
September 30,
2021
December 31,
2020
(In millions)
Non-current long-term debt:
4.375% Notes due 2028
$800 $800 
5.375% Notes due 2022
700 700 
3.875% Notes due 2030
650 650 
Deferred debt issuance costs (20)(23)
Total$2,130 $2,127 
Credit Agreement
We are party to a credit agreement (“Credit Agreement”) which includes a revolving credit facility (“Credit Facility”) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.
The Credit Agreement contains customary non-financial and financial covenants. As of September 30, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September 30, 2021, no amounts were outstanding under the Credit Facility.
High-Yield Senior Notes
Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contains customary non-financial covenants and change of control provisions.
The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.
4.375% Notes due 2028. We had $800 million aggregate principal amount of senior notes (the “4.375% Notes”) outstanding as of September 30, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.
5.375% Notes due 2022. We had $700 million aggregate principal amount of senior notes (the “5.375% Notes”) outstanding as of September 30, 2021, which are due November 15, 2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15.
3.875% Notes due 2030. We had $650 million aggregate principal amount of senior notes (the “3.875% Notes”) outstanding as of September 30, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program immediately supersedes the stock purchase program previously approved by our board of directors in September 2020. This new program will be funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of October 28, 2021, no shares had been purchased under the stock purchase program approved in 2021.
In September 2020, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading
plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In November and December 2020, we purchased 766,000 shares of our common stock for $159 million (average cost of $208.37), including approximately 29,000 shares purchased for $6 million in late December 2020, and settled in early January 2021.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Segments
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segments Segments
In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.
The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.
The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (“MCR”). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.
For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.
The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Total revenue:
Medicaid$5,354 $3,996 $15,583 $11,124 
Medicare875 636 2,502 1,909 
Marketplace793 389 2,224 1,155 
Other18 — 53 — 
Total$7,040 $5,021 $20,362 $14,188 
The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.
September 30,December 31,
20212020
(In millions)
Goodwill:
Medicaid$387 $378 
Medicare247 247 
Other67 67 
Intangibles assets, net:
Medicaid135 157 
Medicare65 76 
Other14 16 
Total$915 $941 
The following table reconciles margin by segment to consolidated income before income taxes.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Margin:
Medicaid$532 $509 $1,687 $1,427 
Medicare151 91 329 333 
Marketplace68 70 331 272 
Other — 11 — 
Total margin 755 670 2,358 2,032 
Add: other operating revenues (1)
222 253 620 744 
Less: other operating expenses (2)
(756)(634)(2,149)(1,789)
Operating income221 289 829 987 
Other expenses, net30 27 90 77 
Income before income tax expense$191 $262 $739 $910 
______________________
(1)Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.
(2)Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
COVID-19 Pandemic
We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.
Legal Proceedings
The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. The consequences associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.
We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Kentucky RFP. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the Court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare of Kentucky and Anthem. The new Medicaid contracts commenced on January 1, 2021. On April 28, 2021, the Court issued its preliminary Opinion and Order, which Opinion and Order the Court finalized on June 16, 2021. Under the final Order, which the Court indicated is immediately appealable by the parties, the Court, among other things, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina’s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the Court ordered a new RFP, with the status quo of six health plans serving Kentucky Medicaid members to continue in the interim. On July 15-16, 2021, each of United, Molina, Humana, and Aetna filed notices of appeal. On July 23, 2021, both the Kentucky Finance and Administration Cabinet and the Kentucky Cabinet for Health and Family Services filed notices of cross appeal, and on July 26, 2021, Anthem filed a notice of cross appeal. This matter remains subject to potential additional legal and appellate proceedings, and no assurances can be given regarding the ultimate outcome. Under the Court’s June 16, 2021 final Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.
Puerto Rico. On August 13, 2021, Molina Healthcare of Puerto, Inc. (MHPR) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (ASES). On September 13, 2021, in addition to filing its answer to MHPR’s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers and, in addition to damages, seeks various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations. This matter is in its early stages, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR’s complaint or the counterclaim of ASES.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Consolidation and Interim Financial Information
Consolidation and Interim Financial Information
The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results for the entire year ending December 31, 2021.
The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, 2020, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, 2020.
Reclassifications
Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.
Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:
The determination of medical claims and benefits payable;
Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;
Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;
Settlements under risk- or savings-sharing programs;
Purchase price allocations relating to business combinations, including the determination of contingent consideration;
The assessment of long-lived and intangible assets, and goodwill for impairment;
The determination of reserves for potential absorption of claims unpaid by insolvent providers;
The determination of reserves for the outcome of litigation;
The determination of valuation allowances for deferred tax assets; and
•The determination of unrecognized tax benefits.
Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.
Receivables
Receivables
Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.
Premium Revenue Recognition and Premiums Receivable
Premium Revenue Recognition and Amounts Due Government Agencies
Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.
Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”
Contractual Provisions That May Adjust or Limit Revenue or ProfitMany of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions.
Medicaid
Minimum MLR and Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable. Our adjustment is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.
Beginning in 2020, through September 30, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three and nine months ended September 30, 2021, we recognized approximately $17 million and $183 million, respectively, related to such risk corridors, primarily in the Medicaid segment.
It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Marketplace
Risk Adjustment. Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.
Income Taxes
Income Taxes
The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.
The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.
Recent Accounting Pronouncements Recent Accounting PronouncementsVarious recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Cash and cash equivalents The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.
September 30,
 20212020
(In millions)
Cash and cash equivalents$4,357 $3,196 
Restricted cash and cash equivalents78 70 
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$4,435 $3,266 
Restricted cash and cash equivalents The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.
September 30,
 20212020
(In millions)
Cash and cash equivalents$4,357 $3,196 
Restricted cash and cash equivalents78 70 
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$4,435 $3,266 
Schedule of receivables
September 30,
2021
December 31,
2020
(In millions)
Government receivables$1,331 $969 
Pharmacy rebate receivables264 178 
Health insurer fee reimbursement receivables25 104 
Other292 255 
Magellan Complete Care acquisition opening balance — 166 
Total$1,912 $1,672 
Amounts due to government agencies Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:
September 30,
2021
December 31,
2020
(In millions)
Medicaid:
Minimum MLR and profit sharing$852 $513 
Other249 76 
Medicare:
Risk adjustment and Part D risk sharing87 45 
Minimum MLR and profit sharing 82 62 
Other41 30 
Marketplace:
Risk adjustment691 326 
Minimum MLR30 37 
Other49 21 
Magellan Complete Care acquisition opening balance— 143 
Total amounts due government agencies$2,081 $1,253 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Summary of denominators for the computation of basic and diluted earnings per share
The following table sets forth the calculation of net income per share:
Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
 (In millions, except net income per share)
Numerator:
Net income$143 $185 $556 $639 
Denominator:
Shares outstanding at the beginning of the period57.8 58.7 58.0 61.9 
Weighted-average number of shares issued:
Stock purchases— — (0.5)(2.8)
Stock-based compensation— — 0.3 0.1 
Denominator for basic net income per share57.8 58.7 57.8 59.2 
Effect of dilutive securities: (1)
Stock-based compensation0.7 0.9 0.7 0.8 
Denominator for diluted net income per share58.5 59.6 58.5 60.0 
Net income per share - Basic (2)
$2.49 $3.14 $9.63 $10.80 
Net income per share - Diluted (2)
$2.46 $3.10 $9.51 $10.65 
______________________________
(1)    The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.
(2)    Source data for calculations in thousands.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair value of assets measured on recurring basis
Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1) (Level 2) (Level 3)
 (In millions)
Corporate debt securities$1,705 $— $1,705 $— 
Mortgage-backed securities610 — 610 — 
U.S. Treasury notes235 — 235 — 
Asset-backed securities224 — 224 — 
Municipal securities97 — 97 — 
Other
29 — 29 — 
Total assets$2,900 $— $2,900 $— 
Contingent consideration liabilities$26 $— $— $26 
Total liabilities$26 $— $— $26 
Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:
Observable InputsDirectly or Indirectly Observable InputsUnobservable Inputs
Total(Level 1)(Level 2)(Level 3)
 (In millions)
Corporate debt securities$1,256 $— $1,256 $— 
Mortgage-backed securities392 — 392 — 
U.S. Treasury notes27 — 27 — 
Asset-backed securities132 — 132 — 
Municipal securities68 — 68 — 
Total assets $1,875 $— $1,875 $— 
Contingent consideration liabilities $46 $— $— $46 
Total liabilities$46 $— $— $46 
Fair value measurements of senior notes
 September 30, 2021December 31, 2020
 Carrying
Amount
Fair Value Carrying
Amount
Fair Value
 (In millions)
4.375% Notes
$790 $835 $789 $843 
5.375% Notes
698 725 697 742 
3.875% Notes
642 688 641 691 
Total$2,130 $2,248 $2,127 $2,276 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Tables)
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments The following tables summarize our investments as of the dates indicated:
 September 30, 2021
Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,688 $19 $$1,705 
Mortgage-backed securities607 610 
U.S. Treasury notes
235 — — 235 
Asset-backed securities223 — 224 
Municipal securities96 — 97 
Other29 — — 29 
Total$2,878 $25 $$2,900 

 December 31, 2020
 Amortized CostGross UnrealizedEstimated Fair Value
 GainsLosses
 (In millions)
Corporate debt securities$1,220 $36 $— $1,256 
Mortgage-backed securities383 10 392 
U.S. Treasury notes
27 — — 27 
Asset-backed securities130 — 132 
Municipal securities66 — 68 
Total$1,826 $50 $$1,875 
Contractual maturities of investments
The contractual maturities of our available-for-sale investments as of September 30, 2021 are summarized below:
Amortized CostEstimated
Fair Value
 (In millions)
Due in one year or less$555 $557 
Due after one year through five years1,530 1,546 
Due after five years through ten years296 298 
Due after ten years497 499 
Total$2,878 $2,900 
Available-for-sale investments
The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of September 30, 2021, and December 31, 2020.
 September 30, 2021December 31, 2020
 Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
Estimated
Fair
Value
Unrealized
Losses
Total
Number of
Positions
 (Dollars in millions)
Corporate debt securities$509 $174 $— $— — 
Mortgage-backed securities
270 94 77 21 
Total$779 $268 $77 $21 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Medical Claims and Benefits Payable (Tables)
9 Months Ended
Sep. 30, 2021
Other Liabilities Disclosure [Abstract]  
Schedule of liability for unpaid claims and claims adjustment expense
The following table provides the details of our medical claims and benefits payable as of the dates indicated:
September 30,
2021
December 31,
2020
 (In millions)
Fee-for-service claims incurred but not paid (“IBNP”)$2,246 $1,647 
Pharmacy payable209 157 
Capitation payable86 70 
Other650 528 
Magellan Complete Care acquisition opening balance— 294 
Total$3,191 $2,696 
Components of the change in medical claims and benefits payable The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for “Components of medical care costs related to: Prior years” represent decreases in medical care costs resulting from actual medical care costs being less than we previously estimated in the prior year.
Nine Months Ended September 30, 2021
Medicaid Medicare MarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$2,129 $392 $175 $2,696 
Components of medical care costs related to:
Current year13,491 2,195 1,872 17,558 
Prior years(158)(36)(22)(216)
Total medical care costs13,333 2,159 1,850 17,342 
Payments for medical care costs related to:
Current year11,530 1,816 1,534 14,880 
Prior years1,538 340 130 2,008 
Total paid13,068 2,156 1,664 16,888 
Change in acquired balances (19)(8)— (27)
Change in non-risk and other provider payables68 — — 68 
Medical claims and benefits payable, ending balance$2,443 $387 $361 $3,191 

Nine Months Ended September 30, 2020
Medicaid MedicareMarketplaceConsolidated
 (In millions)
Medical claims and benefits payable, beginning balance$1,465 $267 $122 $1,854 
Components of medical care costs related to:
Current year9,029 1,588 861 11,478 
Prior years(41)(25)— (66)
Total medical care costs8,988 1,563 861 11,412 
Payments for medical care costs related to:
Current year7,470 1,316 714 9,500 
Prior years1,193 233 101 1,527 
Total paid8,663 1,549 815 11,027 
Change in non-risk and other provider payables50 — — 50 
Medical claims and benefits payable, ending balance$1,840 $281 $168 $2,289 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Long term debt The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:
September 30,
2021
December 31,
2020
(In millions)
Non-current long-term debt:
4.375% Notes due 2028
$800 $800 
5.375% Notes due 2022
700 700 
3.875% Notes due 2030
650 650 
Deferred debt issuance costs (20)(23)
Total$2,130 $2,127 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Segments (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Operating segment information
The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Total revenue:
Medicaid$5,354 $3,996 $15,583 $11,124 
Medicare875 636 2,502 1,909 
Marketplace793 389 2,224 1,155 
Other18 — 53 — 
Total$7,040 $5,021 $20,362 $14,188 
The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.
September 30,December 31,
20212020
(In millions)
Goodwill:
Medicaid$387 $378 
Medicare247 247 
Other67 67 
Intangibles assets, net:
Medicaid135 157 
Medicare65 76 
Other14 16 
Total$915 $941 
The following table reconciles margin by segment to consolidated income before income taxes.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
(In millions)
Margin:
Medicaid$532 $509 $1,687 $1,427 
Medicare151 91 329 333 
Marketplace68 70 331 272 
Other — 11 — 
Total margin 755 670 2,358 2,032 
Add: other operating revenues (1)
222 253 620 744 
Less: other operating expenses (2)
(756)(634)(2,149)(1,789)
Operating income221 289 829 987 
Other expenses, net30 27 90 77 
Income before income tax expense$191 $262 $739 $910 
______________________
(1)Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.
(2)Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Basis of Presentation (Details)
member in Thousands, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 25, 2021
USD ($)
Oct. 07, 2021
USD ($)
Apr. 22, 2021
USD ($)
Sep. 30, 2021
member
position
Sep. 30, 2021
USD ($)
member
position
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
member
position
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
member
Aug. 31, 2021
position
Segment Reporting Information [Line Items]                    
Contract term       4 years            
Net cash paid in business combinations             $ 0 $ 62    
Premium revenue         $ 6,800 $ 4,768 $ 19,689 $ 13,444    
Extension option       2 years            
AgeWell New York | New York                    
Segment Reporting Information [Line Items]                    
Number of members covered | position                   13,000
Premium revenue                 $ 700  
Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan                    
Segment Reporting Information [Line Items]                    
Premium revenue                 $ 1,000  
Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Hidalgo, Tarrant and Northeast Service Areas                    
Segment Reporting Information [Line Items]                    
Number of members covered | member                 48  
Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Hidalgo Service Area                    
Segment Reporting Information [Line Items]                    
Number of members covered | member                 2  
New York Acquisition—Medicaid | Subsequent event                    
Segment Reporting Information [Line Items]                    
Net cash paid in business combinations $ 380                  
Total Purchase price   $ 110                
Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan                    
Segment Reporting Information [Line Items]                    
Total Purchase price     $ 60              
Health Plans                    
Segment Reporting Information [Line Items]                    
Number of members eligible for the health care programs, approximately | member       4,800 4,800   4,800      
Number of states with programs | position       18 18   18      
Minimum | Health Plans                    
Segment Reporting Information [Line Items]                    
Contract term             3 years      
Maximum | Health Plans                    
Segment Reporting Information [Line Items]                    
Contract term             5 years      
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Accounting Policies [Abstract]        
Cash and cash equivalents $ 4,357 $ 4,154 $ 3,196  
Restricted cash and cash equivalents 78   70  
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows $ 4,435 $ 4,223 $ 3,266 $ 2,508
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies - Receivables (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables $ 1,912 $ 1,672
Government receivables    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables 1,331 969
Pharmacy rebate receivables    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables 264 178
Health insurer fee reimbursement receivables    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables 25 104
Other    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables 292 255
Magellan Complete Care acquisition opening balance    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total receivables $ 0 $ 166
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Medicaid:    
Minimum MLR and profit sharing $ 852 $ 513
Other 249 76
Medicare:    
Risk adjustment and Part D risk sharing 87 45
Minimum MLR and profit sharing 82 62
Other 41 30
Marketplace:    
Risk adjustment 691 326
Minimum MLR 30 37
Other 49 21
Magellan Complete Care acquisition opening balance 0 143
Medical Premium Liability Due To Agency $ 2,081 $ 1,253
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Schedule of Premium Revenue by Health Plan Type [Line Items]        
Risk adjustment payable $ 691 $ 691 $ 326  
Risk adjustment receivable 29 29 20  
Risk adjustment, net payable 662 662 $ 306  
Risk adjustment, net payable, current year (660) $ (660)    
Risk adjustment, net payable, prior year       $ (2)
Maturity period (less than)   10 years    
Structured Securities        
Schedule of Premium Revenue by Health Plan Type [Line Items]        
Average maturity period (less than)   10 years    
COVID-19        
Schedule of Premium Revenue by Health Plan Type [Line Items]        
Reduction in premiums $ 17 $ 183    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Numerator:                    
Net income $ 143 $ 185 $ 228 $ 185 $ 276 $ 178 $ 556 $ 639    
Denominator:                    
Shares outstanding at the beginning of the period (in shares)   57.8     58.7       58.0 61.9
Weighted-average number of shares issued:                    
Stock purchases (in shares) 0.0     0.0     (0.5) (2.8)    
Stock-based compensation (in shares) 0.0     0.0     0.3 0.1    
Denominator for basic net income per share (in shares) 57.8     58.7     57.8 59.2    
Effect of dilutive securities:                    
Stock-based compensation (in shares) 0.7     0.9     0.7 0.8    
Denominator for diluted net income per share (in shares) 58.5     59.6     58.5 60.0    
Net income per share:                    
Net income per share - Basic (in dollars per share) $ 2.49     $ 3.14     $ 9.63 $ 10.80    
Net income per share - Diluted (in dollars per share) $ 2.46     $ 3.10     $ 9.51 $ 10.65    
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combinations - Narrative (Details) - Magellan complete care - USD ($)
$ in Millions
9 Months Ended
Dec. 31, 2020
Sep. 30, 2021
Business Acquisition, Contingent Consideration [Line Items]    
Outstanding equity interests 100.00%  
Total Purchase price $ 1,037  
Receivables   $ 7
Payable   27
Amounts due government agencies   18
Goodwill   $ 9
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale $ 2,900 $ 1,875
Total assets 2,900 1,875
Contingent consideration liabilities 26 46
Total liabilities 26 46
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 1,705 1,256
Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 610 392
U.S. Treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 235 27
Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 224 132
Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 97 68
Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 29  
(Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 0 0
Contingent consideration liabilities 0 0
Total liabilities 0 0
(Level 1) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 1) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 1) | U.S. Treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 1) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 1) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 1) | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0  
(Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 2,900 1,875
Contingent consideration liabilities 0 0
Total liabilities 0 0
(Level 2) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 1,705 1,256
(Level 2) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 610 392
(Level 2) | U.S. Treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 235 27
(Level 2) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 224 132
(Level 2) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 97 68
(Level 2) | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 29  
(Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 0 0
Contingent consideration liabilities   46
Total liabilities 26 46
(Level 3) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 3) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 3) | U.S. Treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 3) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 0
(Level 3) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale 0 $ 0
(Level 3) | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale $ 0  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Recognized loss $ 3  
Contingent consideration liabilities 26 $ 46
(Level 3)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Contingent consideration liabilities   $ 46
Passport Health Plan, Inc.    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Paid to seller 23  
Passport Health Plan, Inc. | (Level 3)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Contingent consideration liabilities $ 26  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Long-Term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 2,130 $ 2,127
Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 2,248 2,276
Senior notes | 4.375% Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, interest rate, stated percentage 4.375%  
Senior notes | 4.375% Notes | Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 790 789
Senior notes | 4.375% Notes | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 835 843
Senior notes | 5.375% Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, interest rate, stated percentage 5.375%  
Senior notes | 5.375% Notes | Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 698 697
Senior notes | 5.375% Notes | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 725 742
Senior notes | 3.875% Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt instrument, interest rate, stated percentage 3.875%  
Senior notes | 3.875% Notes | Carrying Amount    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 642 641
Senior notes | 3.875% Notes | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of debt $ 688 $ 691
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Summary of Investments (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 2,878 $ 1,826
Gross unrealized gains 25 50
Gross unrealized losses 3 1
Estimated Fair Value 2,900 1,875
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 1,688 1,220
Gross unrealized gains 19 36
Gross unrealized losses 2 0
Estimated Fair Value 1,705 1,256
Mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 607 383
Gross unrealized gains 4 10
Gross unrealized losses 1 1
Estimated Fair Value 610 392
U.S. Treasury notes    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 235 27
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Estimated Fair Value 235 27
Asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 223 130
Gross unrealized gains 1 2
Gross unrealized losses 0 0
Estimated Fair Value 224 132
Municipal securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 96 66
Gross unrealized gains 1 2
Gross unrealized losses 0 0
Estimated Fair Value 97 $ 68
Other    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 29  
Gross unrealized gains 0  
Gross unrealized losses 0  
Estimated Fair Value $ 29  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Contractual Maturities of Available-for-Sale Investments (Details)
$ in Millions
Sep. 30, 2021
USD ($)
Amortized Cost  
Due in one year or less $ 555
Due after one year through five years 1,530
Due after five years through ten years 296
Due after ten years 497
Amortized Cost 2,878
Estimated Fair Value  
Due in one year or less 557
Due after one year through five years 1,546
Due after five years through ten years 298
Due after ten years 499
Estimated Fair Value $ 2,900
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]      
Gross realized investment gains $ 6 $ 7 $ 6
Debt securities held to maturity 156 156  
Amortized Cost, Due in one year or less 148 148  
Amortized Cost, Due one year through five years $ 8 $ 8  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Available-for-Sale Investments (Details)
$ in Millions
Sep. 30, 2021
USD ($)
position
Dec. 31, 2020
USD ($)
position
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 779 $ 77
Unrealized Losses $ 3 $ 1
Total Number of Positions | position 268 21
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 509 $ 0
Unrealized Losses $ 2 $ 0
Total Number of Positions | position 174 0
Mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 270 $ 77
Unrealized Losses $ 1 $ 1
Total Number of Positions | position 94 21
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Liability for Claims and Claims Adjustment Expense [Line Items]        
Fee-for-service claims incurred but not paid (“IBNP”) $ 2,246 $ 1,647    
Pharmacy payable 209 157    
Capitation payable 86 70    
Other 650 528    
Total 3,191 2,696 $ 2,289 $ 1,854
Magellan complete care        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Total $ 0 $ 294    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Medical Claims and Benefits Payable - Narrative (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Other Liabilities Disclosure [Abstract]      
Non-risk provider payables $ 301   $ 235
Prior period claims, favorable development $ (216) $ (66)  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Insurance Claims    
Medical claims and benefits payable, beginning balance $ 2,696 $ 1,854
Components of medical care costs related to:    
Current year 17,558 11,478
Prior years (216) (66)
Total medical care costs 17,342 11,412
Payments for medical care costs related to:    
Current year 14,880 9,500
Prior years 2,008 1,527
Total paid 16,888 11,027
Change in acquired balances (27)  
Change in non-risk and other provider payables 68 50
Medical claims and benefits payable, ending balance 3,191 2,289
Medicaid    
Insurance Claims    
Medical claims and benefits payable, beginning balance 2,129 1,465
Components of medical care costs related to:    
Current year 13,491 9,029
Prior years (158) (41)
Total medical care costs 13,333 8,988
Payments for medical care costs related to:    
Current year 11,530 7,470
Prior years 1,538 1,193
Total paid 13,068 8,663
Change in acquired balances (19)  
Change in non-risk and other provider payables 68 50
Medical claims and benefits payable, ending balance 2,443 1,840
Medicare    
Insurance Claims    
Medical claims and benefits payable, beginning balance 392 267
Components of medical care costs related to:    
Current year 2,195 1,588
Prior years (36) (25)
Total medical care costs 2,159 1,563
Payments for medical care costs related to:    
Current year 1,816 1,316
Prior years 340 233
Total paid 2,156 1,549
Change in acquired balances (8)  
Change in non-risk and other provider payables 0 0
Medical claims and benefits payable, ending balance 387 281
Marketplace    
Insurance Claims    
Medical claims and benefits payable, beginning balance 175 122
Components of medical care costs related to:    
Current year 1,872 861
Prior years (22) 0
Total medical care costs 1,850 861
Payments for medical care costs related to:    
Current year 1,534 714
Prior years 130 101
Total paid 1,664 815
Change in acquired balances 0  
Change in non-risk and other provider payables 0 0
Medical claims and benefits payable, ending balance $ 361 $ 168
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Deferred debt issuance costs $ (20) $ (23)
Total $ 2,130 2,127
Senior notes | 4.375% Notes    
Debt Instrument [Line Items]    
Percentage of contractual interest rate on notes 4.375%  
Non-current portion of long-term debt $ 800 800
Senior notes | 5.375% Notes    
Debt Instrument [Line Items]    
Percentage of contractual interest rate on notes 5.375%  
Non-current portion of long-term debt $ 700 700
Senior notes | 3.875% Notes    
Debt Instrument [Line Items]    
Percentage of contractual interest rate on notes 3.875%  
Non-current portion of long-term debt $ 650 $ 650
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Narrative (Details)
9 Months Ended
Sep. 30, 2021
USD ($)
Line of Credit  
Debt Instrument [Line Items]  
Debt term 5 years
Line of Credit | Credit facility  
Debt Instrument [Line Items]  
Maximum borrowing capacity $ 1,000,000,000
Amount outstanding under letter of credit $ 0
Senior notes | 4.375% Notes  
Debt Instrument [Line Items]  
Percentage of contractual interest rate on notes 4.375%
Face amount $ 800,000,000
Senior notes | 5.375% Notes  
Debt Instrument [Line Items]  
Percentage of contractual interest rate on notes 5.375%
Face amount $ 700,000,000
Senior notes | 3.875% Notes  
Debt Instrument [Line Items]  
Percentage of contractual interest rate on notes 3.875%
Face amount $ 650,000,000
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Dec. 31, 2020
Feb. 28, 2021
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Class of Stock [Line Items]                  
Repurchased of common stock           $ 122,000,000 $ 446,000,000    
Payments to settle shares purchased               $ 128,000,000 $ 453,000,000
Common Stock                  
Class of Stock [Line Items]                  
Common stock authorized               $ 500,000,000 $ 500,000,000
Repurchased of common stock (in shares)   577 29   766 1,000 3,000    
Repurchased of common stock $ 122,000,000       $ 159,000,000        
Average cost (USD per share)       $ 211.65 $ 208.37        
Payments to settle shares purchased     $ 6,000,000            
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]          
Total revenue $ 7,040 $ 5,021 $ 20,362 $ 14,188  
Total 915   915   $ 941
Less: other operating expenses (6,819) (4,732) (19,533) (13,201)  
Operating income 221 289 829 987  
Other expenses, net 30 27 90 77  
Income before income tax expense 191 262 739 910  
Medicaid          
Segment Reporting Information [Line Items]          
Total revenue 5,354 3,996 15,583 11,124  
Goodwill 387   387   378
Intangible assets, net 135   135   157
Medicare          
Segment Reporting Information [Line Items]          
Total revenue 875 636 2,502 1,909  
Goodwill 247   247   247
Intangible assets, net 65   65   76
Marketplace          
Segment Reporting Information [Line Items]          
Total revenue 793 389 2,224 1,155  
Other          
Segment Reporting Information [Line Items]          
Total revenue 18 0 53 0  
Goodwill 67   67   67
Intangible assets, net 14   14   $ 16
Operating segments          
Segment Reporting Information [Line Items]          
Total margin 755 670 2,358 2,032  
Operating segments | Medicaid          
Segment Reporting Information [Line Items]          
Total margin 532 509 1,687 1,427  
Operating segments | Medicare          
Segment Reporting Information [Line Items]          
Total margin 151 91 329 333  
Operating segments | Marketplace          
Segment Reporting Information [Line Items]          
Total margin 68 70 331 272  
Operating segments | Other          
Segment Reporting Information [Line Items]          
Total margin 4 0 11 0  
Other operating          
Segment Reporting Information [Line Items]          
Total revenue 222 253 620 744  
Less: other operating expenses $ (756) $ (634) $ (2,149) $ (1,789)  
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 235 310 1 false 47 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.molinahealthcare.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Organization and Basis of Presentation Sheet http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 2103102 - Disclosure - Significant Accounting Policies Sheet http://www.molinahealthcare.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 2110103 - Disclosure - Net Income per Share Sheet http://www.molinahealthcare.com/role/NetIncomeperShare Net Income per Share Notes 10 false false R11.htm 2113104 - Disclosure - Business Combinations Sheet http://www.molinahealthcare.com/role/BusinessCombinations Business Combinations Notes 11 false false R12.htm 2115105 - Disclosure - Fair Value Measurements Sheet http://www.molinahealthcare.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2120106 - Disclosure - Investments Sheet http://www.molinahealthcare.com/role/Investments Investments Notes 13 false false R14.htm 2126107 - Disclosure - Medical Claims and Benefits Payable Sheet http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable Medical Claims and Benefits Payable Notes 14 false false R15.htm 2131108 - Disclosure - Debt Sheet http://www.molinahealthcare.com/role/Debt Debt Notes 15 false false R16.htm 2135109 - Disclosure - Stockholders' Equity Sheet http://www.molinahealthcare.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 2137110 - Disclosure - Segments Sheet http://www.molinahealthcare.com/role/Segments Segments Notes 17 false false R18.htm 2140111 - Disclosure - Commitments and Contingencies Sheet http://www.molinahealthcare.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 2204201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.molinahealthcare.com/role/SignificantAccountingPolicies 19 false false R20.htm 2305301 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.molinahealthcare.com/role/SignificantAccountingPolicies 20 false false R21.htm 2311302 - Disclosure - Net Income per Share (Tables) Sheet http://www.molinahealthcare.com/role/NetIncomeperShareTables Net Income per Share (Tables) Tables http://www.molinahealthcare.com/role/NetIncomeperShare 21 false false R22.htm 2316303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.molinahealthcare.com/role/FairValueMeasurements 22 false false R23.htm 2321304 - Disclosure - Investments (Tables) Sheet http://www.molinahealthcare.com/role/InvestmentsTables Investments (Tables) Tables http://www.molinahealthcare.com/role/Investments 23 false false R24.htm 2327305 - Disclosure - Medical Claims and Benefits Payable (Tables) Sheet http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables Medical Claims and Benefits Payable (Tables) Tables http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable 24 false false R25.htm 2332306 - Disclosure - Debt (Tables) Sheet http://www.molinahealthcare.com/role/DebtTables Debt (Tables) Tables http://www.molinahealthcare.com/role/Debt 25 false false R26.htm 2338307 - Disclosure - Segments (Tables) Sheet http://www.molinahealthcare.com/role/SegmentsTables Segments (Tables) Tables http://www.molinahealthcare.com/role/Segments 26 false false R27.htm 2402401 - Disclosure - Organization and Basis of Presentation (Details) Sheet http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails Organization and Basis of Presentation (Details) Details http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation 27 false false R28.htm 2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) Details 28 false false R29.htm 2407403 - Disclosure - Significant Accounting Policies - Receivables (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails Significant Accounting Policies - Receivables (Details) Details 29 false false R30.htm 2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails Significant Accounting Policies - Amounts Due To Government Agencies (Details) Details 30 false false R31.htm 2409405 - Disclosure - Significant Accounting Policies - Narrative (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies - Narrative (Details) Details 31 false false R32.htm 2412406 - Disclosure - Net Income per Share (Details) Sheet http://www.molinahealthcare.com/role/NetIncomeperShareDetails Net Income per Share (Details) Details http://www.molinahealthcare.com/role/NetIncomeperShareTables 32 false false R33.htm 2414407 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 33 false false R34.htm 2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) Details 34 false false R35.htm 2418409 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 35 false false R36.htm 2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails Fair Value Measurements - Long-Term Debt (Details) Details 36 false false R37.htm 2422411 - Disclosure - Investments - Summary of Investments (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails Investments - Summary of Investments (Details) Details 37 false false R38.htm 2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails Investments - Contractual Maturities of Available-for-Sale Investments (Details) Details 38 false false R39.htm 2424413 - Disclosure - Investments - Narrative (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 39 false false R40.htm 2425414 - Disclosure - Investments - Available-for-Sale Investments (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails Investments - Available-for-Sale Investments (Details) Details 40 false false R41.htm 2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) Details 41 false false R42.htm 2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails Medical Claims and Benefits Payable - Narrative (Details) Details 42 false false R43.htm 2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) Details 43 false false R44.htm 2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details) Sheet http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails Debt - Schedule of Long-Term Debt (Details) Details 44 false false R45.htm 2434419 - Disclosure - Debt - Narrative (Details) Sheet http://www.molinahealthcare.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 45 false false R46.htm 2436420 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 46 false false R47.htm 2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details) Sheet http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails Segments - Reconciliation of Gross Margin to Consolidated Income (Details) Details 47 false false All Reports Book All Reports moh-20210930.htm moh-20210930.xsd moh-20210930_cal.xml moh-20210930_def.xml moh-20210930_lab.xml moh-20210930_pre.xml moh3q21_ex311.htm moh3q21_ex312.htm moh3q21_ex321.htm moh3q21_ex322.htm moh-20210930_g1.jpg http://xbrl.sec.gov/stpr/2021 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "moh-20210930.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 235, "dts": { "calculationLink": { "local": [ "moh-20210930_cal.xml" ] }, "definitionLink": { "local": [ "moh-20210930_def.xml" ] }, "inline": { "local": [ "moh-20210930.htm" ] }, "labelLink": { "local": [ "moh-20210930_lab.xml" ] }, "presentationLink": { "local": [ "moh-20210930_pre.xml" ] }, "schema": { "local": [ "moh-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 390, "entityCount": 1, "hidden": { "http://www.molinahealthcare.com/20210930": 1, "http://xbrl.sec.gov/dei/2021": 5, "total": 6 }, "keyCustom": 43, "keyStandard": 267, "memberCustom": 23, "memberStandard": 23, "nsprefix": "moh", "nsuri": "http://www.molinahealthcare.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.molinahealthcare.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - Net Income per Share", "role": "http://www.molinahealthcare.com/role/NetIncomeperShare", "shortName": "Net Income per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Business Combinations", "role": "http://www.molinahealthcare.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115105 - Disclosure - Fair Value Measurements", "role": "http://www.molinahealthcare.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Investments", "role": "http://www.molinahealthcare.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Medical Claims and Benefits Payable", "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable", "shortName": "Medical Claims and Benefits Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131108 - Disclosure - Debt", "role": "http://www.molinahealthcare.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135109 - Disclosure - Stockholders' Equity", "role": "http://www.molinahealthcare.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Segments", "role": "http://www.molinahealthcare.com/role/Segments", "shortName": "Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Commitments and Contingencies", "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "moh:HealthCareOrganizationPremiumTaxRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Net Income per Share (Tables)", "role": "http://www.molinahealthcare.com/role/NetIncomeperShareTables", "shortName": "Net Income per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Investments (Tables)", "role": "http://www.molinahealthcare.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables", "shortName": "Medical Claims and Benefits Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Debt (Tables)", "role": "http://www.molinahealthcare.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Segments (Tables)", "role": "http://www.molinahealthcare.com/role/SegmentsTables", "shortName": "Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ie7aa14a610b44427b9a65bbc11cf9522_D20210901-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:HealthPlanContractTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)", "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "shortName": "Organization and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ie7aa14a610b44427b9a65bbc11cf9522_D20210901-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "moh:HealthPlanContractTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i3f65c9ae15f34cecb9adaa16424da61d_I20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails", "shortName": "Significant Accounting Policies - Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i6878ae80441b4f02a74418eb283d98e5_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails", "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i0237f2a8165a415193fdd10381b9b384_I20201231", "decimals": "-6", "lang": "en-US", "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Net Income per Share (Details)", "role": "http://www.molinahealthcare.com/role/NetIncomeperShareDetails", "shortName": "Net Income per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ib19864b0d35b407ebe78e15d4d0257bb_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Business Combinations - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails", "shortName": "Business Combinations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ib19864b0d35b407ebe78e15d4d0257bb_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i2fa7df3e2b55467699bdcea9cef924fd_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "shortName": "Fair Value Measurements - Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i2fa7df3e2b55467699bdcea9cef924fd_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Investments - Summary of Investments (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails", "shortName": "Investments - Summary of Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails", "shortName": "Investments - Contractual Maturities of Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Investments - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "shortName": "Investments - Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails", "shortName": "Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:MedicalClaimsAndBenefitsPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails", "shortName": "Medical Claims and Benefits Payable - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "moh:MedicalClaimsAndBenefitsPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i0237f2a8165a415193fdd10381b9b384_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "shortName": "Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)", "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "shortName": "Debt - Schedule of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ia0e395b7eedf41bfa40a8f5b96451346_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - Debt - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "ia0e395b7eedf41bfa40a8f5b96451346_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i9bc7679c771b48e99c654be71c1df089_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Stockholders' Equity - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i1310d5736d744e138c37f568f83844d5_I20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i29f78af976c146098ebf23b7323f80e2_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)", "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails", "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i134c815781c34a808c73754c1bf24989_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "iccea7eee8c0c4ca0969d09463f992b06_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "i023faddb8c814a3ba5fe172dcfa9799e_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "if04a6f6170cf4853a9d950d2ee21fa7e_D20200101-20200331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Basis of Presentation", "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Significant Accounting Policies", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20210930.htm", "contextRef": "id55c2c177d044f6b8df9aa1fc5c61614_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "moh_A4375SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.375% Senior Notes", "label": "4.375% Senior Notes [Member]", "terseLabel": "4.375% Notes" } } }, "localname": "A4375SeniorNotesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable", "terseLabel": "Risk adjustment, net payable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years", "terseLabel": "Risk adjustment, net payable, prior year" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)", "terseLabel": "Risk adjustment payable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable", "terseLabel": "Risk adjustment receivable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year", "verboseLabel": "Risk adjustment, net payable, current year" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_AgeWellNewYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AgeWell New York", "label": "AgeWell New York [Member]", "terseLabel": "AgeWell New York" } } }, "localname": "AgeWellNewYorkMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_AmountsDueToGovernmentAgenciesBusinessCombination": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 5.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due to Government Agencies, Business Combination", "label": "Amounts Due to Government Agencies, Business Combination", "terseLabel": "Magellan Complete Care acquisition opening balance" } } }, "localname": "AmountsDueToGovernmentAgenciesBusinessCombination", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 3.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold", "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold", "terseLabel": "Minimum MLR" } } }, "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]", "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]", "terseLabel": "Marketplace:" } } }, "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "stringItemType" }, "moh_AmountsDueToGovernmentAgenciesMedicaidOther": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 6.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies, Medicaid, Other", "label": "Amounts Due To Government Agencies, Medicaid, Other", "terseLabel": "Other" } } }, "localname": "AmountsDueToGovernmentAgenciesMedicaidOther", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]", "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]", "terseLabel": "Medicaid:" } } }, "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "stringItemType" }, "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 4.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold", "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold", "terseLabel": "Minimum MLR and profit sharing" } } }, "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts Due To Government Agencies Medicare Program", "label": "Amounts Due To Government Agencies Medicare Program [Abstract]", "terseLabel": "Medicare:" } } }, "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "stringItemType" }, "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 1.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing", "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing", "terseLabel": "Risk adjustment and Part D risk sharing" } } }, "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesOther": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 7.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due to Government Agencies, Other", "label": "Amounts Due to Government Agencies, Other", "terseLabel": "Other" } } }, "localname": "AmountsDuetoGovernmentAgenciesOther", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 8.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts Due to Government Agencies, Risk Adjustment", "label": "Amounts Due to Government Agencies, Risk Adjustment", "terseLabel": "Risk adjustment" } } }, "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of members eligible for the health care programs.", "label": "Business Combination, Number Of Members Eligible For The Health Care Programs", "terseLabel": "Number of members eligible for the health care programs, approximately" } } }, "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies", "terseLabel": "Amounts due government agencies" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable", "terseLabel": "Payable" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables", "terseLabel": "Receivables" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "moh_CapitationClaimsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capitation Claims Payable", "label": "Capitation Claims Payable", "terseLabel": "Capitation payable" } } }, "localname": "CapitationClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_ChangeInAcquiredBalances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change In Acquired Balances", "label": "Change In Acquired Balances", "terseLabel": "Change in acquired balances" } } }, "localname": "ChangeInAcquiredBalances", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan", "label": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]", "terseLabel": "Texas Acquisition - Medicaid and Medicare", "verboseLabel": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan" } } }, "localname": "CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_CommonStockWithheldToSettleEmployeeTaxObligations": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Stock Withheld to Settle Employee Tax Obligations", "label": "Common Stock Withheld to Settle Employee Tax Obligations", "negatedLabel": "Common stock withheld to settle employee tax obligations" } } }, "localname": "CommonStockWithheldToSettleEmployeeTaxObligations", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "moh_CompleteCareReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Complete Care Receivables", "label": "Complete Care Receivables [Member]", "terseLabel": "Magellan Complete Care acquisition opening balance" } } }, "localname": "CompleteCareReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]", "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]", "terseLabel": "Components of the change in medical claims and benefits payable" } } }, "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "moh_ComponentsOfMedicalCareCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of medical care costs.", "label": "Components Of Medical Care Costs [Abstract]", "terseLabel": "Components of medical care costs related to:" } } }, "localname": "ComponentsOfMedicalCareCostsAbstract", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "stringItemType" }, "moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidation And Interim Financial Information, Policy [Policy Text Block]", "label": "Consolidation And Interim Financial Information, Policy [Policy Text Block]", "terseLabel": "Consolidation and Interim Financial Information" } } }, "localname": "ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "moh_GovernmentReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Receivables [Member]", "label": "Government Receivables [Member]", "terseLabel": "Government receivables" } } }, "localname": "GovernmentReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_HealthCareOrganizationInsurerFeeExpense": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Health Care Organization, Insurer Fee Expense", "label": "Health Care Organization, Insurer Fee Expense", "terseLabel": "Health insurer fees" } } }, "localname": "HealthCareOrganizationInsurerFeeExpense", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "moh_HealthCareOrganizationInsurerFeeRevenue": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 5.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Health Care Organization, Insurer Fee Revenue", "label": "Health Care Organization, Insurer Fee Revenue", "terseLabel": "Health insurer fees reimbursed" } } }, "localname": "HealthCareOrganizationInsurerFeeRevenue", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "moh_HealthCareOrganizationPremiumTaxRevenue": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Health Care Organization, Premium Tax Revenue", "label": "Health Care Organization, Premium Tax Revenue", "terseLabel": "Premium tax revenue" } } }, "localname": "HealthCareOrganizationPremiumTaxRevenue", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "moh_HealthInsurerFeeReimbursementReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Insurer Fee Reimbursement Receivables [Member]", "label": "Health Insurer Fee Reimbursement Receivables [Member]", "terseLabel": "Health insurer fee reimbursement receivables" } } }, "localname": "HealthInsurerFeeReimbursementReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_HealthPlanContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Plan, Contract Term", "label": "Health Plan, Contract Term", "terseLabel": "Contract term" } } }, "localname": "HealthPlanContractTerm", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "durationItemType" }, "moh_HealthPlanExtensionOptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Plan, Extension Option, Period", "label": "Health Plan, Extension Option, Period", "terseLabel": "Extension option" } } }, "localname": "HealthPlanExtensionOptionPeriod", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "durationItemType" }, "moh_HealthPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health plans.", "label": "Health Plans [Member]", "terseLabel": "Health Plans", "verboseLabel": "Medicaid" } } }, "localname": "HealthPlansMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "moh_HidalgoServiceAreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hidalgo Service Area", "label": "Hidalgo Service Area [Member]", "terseLabel": "Hidalgo Service Area" } } }, "localname": "HidalgoServiceAreaMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_HidalgoTarrantAndNortheastServiceAreasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hidalgo, Tarrant and Northeast Service Areas", "label": "Hidalgo, Tarrant and Northeast Service Areas [Member]", "terseLabel": "Hidalgo, Tarrant and Northeast Service Areas" } } }, "localname": "HidalgoTarrantAndNortheastServiceAreasMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency", "label": "Increase (Decrease) In Medical Premium Liability Due To Agency", "terseLabel": "Amounts due government agencies" } } }, "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "moh_InvestmentsAverageMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments, Average Maturity Period", "label": "Investments, Average Maturity Period", "terseLabel": "Average maturity period (less than)" } } }, "localname": "InvestmentsAverageMaturityPeriod", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "moh_InvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments, Maturity Period", "label": "Investments, Maturity Period", "terseLabel": "Maturity period (less than)" } } }, "localname": "InvestmentsMaturityPeriod", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount", "terseLabel": "Fee-for-service claims incurred but not paid (\u201cIBNP\u201d)" } } }, "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount", "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount", "terseLabel": "Non-current portion of long-term debt" } } }, "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "moh_MagellanCompleteCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Magellan Complete Care [Member]", "label": "Magellan Complete Care [Member]", "terseLabel": "Magellan complete care" } } }, "localname": "MagellanCompleteCareMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "domainItemType" }, "moh_MarketplaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketplace", "label": "Marketplace [Member]", "terseLabel": "Marketplace" } } }, "localname": "MarketplaceMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "moh_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "domainItemType" }, "moh_MedicalClaimsAndBenefitsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medical Claims and Benefits Payable", "label": "Medical Claims And Benefits Payable", "terseLabel": "Non-risk provider payables" } } }, "localname": "MedicalClaimsAndBenefitsPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider", "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider", "terseLabel": "Change in non-risk and other provider payables" } } }, "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalClaimsAndBenefitsPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical claims and benefits payable.", "label": "Medical Claims And Benefits Payable [Text Block]", "terseLabel": "Medical Claims and Benefits Payable" } } }, "localname": "MedicalClaimsAndBenefitsPayableTextBlock", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" ], "xbrltype": "textBlockItemType" }, "moh_MedicalPremiumLiabilityDueToAgency": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medical Premium Liability Due to Agency", "label": "Medical Premium Liability Due To Agency", "terseLabel": "Amounts due government agencies", "totalLabel": "Medical Premium Liability Due To Agency" } } }, "localname": "MedicalPremiumLiabilityDueToAgency", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 9.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medical Premiums Liability, Medical Care Costs Threshold", "label": "Medical Premiums Liability, Medical Care Costs Threshold", "terseLabel": "Minimum MLR and profit sharing" } } }, "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "moh_MunicipalSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Municipal securities.", "label": "Municipal Securities [Member]", "terseLabel": "Municipal securities" } } }, "localname": "MunicipalSecuritiesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "moh_NewYorkAcquisitionMedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Acquisition\u2014Medicaid", "label": "New York Acquisition\u2014Medicaid [Member]", "terseLabel": "New York Acquisition\u2014Medicaid" } } }, "localname": "NewYorkAcquisitionMedicaidMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_NumberOfMembersCovered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Members Covered", "label": "Number of Members Covered", "terseLabel": "Number of members covered" } } }, "localname": "NumberOfMembersCovered", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of States With Government-Sponsored Healthcare Programs", "label": "Number Of States With Government-Sponsored Healthcare Programs", "terseLabel": "Number of states with programs" } } }, "localname": "NumberOfStatesWithGovernmentSponsoredHealthcarePrograms", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_OtherClaimsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Claims Payable", "label": "Other Claims Payable", "terseLabel": "Other" } } }, "localname": "OtherClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_OtherMedicareProgram": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": { "order": 2.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Medicare Program", "label": "Other Medicare Program", "terseLabel": "Other" } } }, "localname": "OtherMedicareProgram", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Receivables [Member]", "label": "Other Receivables [Member]", "terseLabel": "Other" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_OtherSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Securities", "label": "Other Securities [Member]", "terseLabel": "Other" } } }, "localname": "OtherSecuritiesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "moh_PassportHealthPlanIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Passport Health Plan Inc", "label": "Passport Health Plan Inc [Member]", "terseLabel": "Passport Health Plan, Inc." } } }, "localname": "PassportHealthPlanIncMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "moh_PaymentsForMedicalCareCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments for medical care costs.", "label": "Payments For Medical Care Costs [Abstract]", "terseLabel": "Payments for medical care costs related to:" } } }, "localname": "PaymentsForMedicalCareCostsAbstract", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "stringItemType" }, "moh_PharmacyClaimsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pharmacy Claims Payable", "label": "Pharmacy Claims Payable", "terseLabel": "Pharmacy payable" } } }, "localname": "PharmacyClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "moh_PharmacyRebateReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Rebate Receivables [Member]", "label": "Pharmacy Rebate Receivables [Member]", "terseLabel": "Pharmacy rebate receivables" } } }, "localname": "PharmacyRebateReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_PremiumTaxExpenses": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An assessment levied by a state government on the net premium income collected.", "label": "Premium Tax Expenses", "terseLabel": "Premium tax expenses" } } }, "localname": "PremiumTaxExpenses", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of premium revenue by health plan type.", "label": "Schedule of Premium Revenue by Health Plan Type [Line Items]", "terseLabel": "Schedule of Premium Revenue by Health Plan Type [Line Items]" } } }, "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeLineItems", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of premium revenue by health plan type.", "label": "Schedule of Premium Revenue by Health Plan Type [Table]", "terseLabel": "Schedule Of Premium Revenue By Health Plan Type [Table]" } } }, "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeTable", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "moh_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2022 [Member]", "label": "Senior Notes Due 2022 [Member]", "terseLabel": "5.375% Notes" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_StructuredSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structured Securities [Member]", "label": "Structured Securities [Member]", "terseLabel": "Structured Securities" } } }, "localname": "StructuredSecuritiesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "moh_ThreePointEightSevenFivePercentSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Eight Seven Five Percent Senior Notes", "label": "Three Point Eight Seven Five Percent Senior Notes [Member]", "terseLabel": "3.875% Notes" } } }, "localname": "ThreePointEightSevenFivePercentSeniorNotesMember", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_WeightedAverageNumberofSharesShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number of Shares, Share Based Compensation", "label": "Weighted Average Number of Shares, Share Based Compensation", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "WeightedAverageNumberofSharesShareBasedCompensation", "nsuri": "http://www.molinahealthcare.com/20210930", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r97", "r144", "r157", "r158", "r159", "r160", "r162", "r164", "r168", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r244", "r246", "r248", "r249" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r97", "r144", "r157", "r158", "r159", "r160", "r162", "r164", "r168", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r244", "r246", "r248", "r249" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r254", "r281", "r329", "r331", "r418", "r419", "r420", "r421", "r422", "r423", "r442", "r493", "r495", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r254", "r281", "r329", "r331", "r418", "r419", "r420", "r421", "r422", "r423", "r442", "r493", "r495", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r254", "r281", "r319", "r329", "r331", "r418", "r419", "r420", "r421", "r422", "r423", "r442", "r493", "r495", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r254", "r281", "r319", "r329", "r331", "r418", "r419", "r420", "r421", "r422", "r423", "r442", "r493", "r495", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r171", "r172", "r315", "r317", "r494", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r171", "r172", "r315", "r317", "r494", "r506", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK", "terseLabel": "New York" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued liabilities and other" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r43", "r45", "r46", "r475", "r500", "r501" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r46", "r54", "r55", "r56", "r99", "r100", "r101", "r371", "r496", "r497", "r535" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r99", "r100", "r101", "r334", "r335", "r336", "r378" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Termination of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r140", "r157", "r158", "r159", "r160", "r162" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "verboseLabel": "Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r193", "r320" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r95", "r152", "r159", "r166", "r203", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r368", "r372", "r391", "r408", "r410", "r449", "r473" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r8", "r38", "r95", "r203", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r368", "r372", "r391", "r408", "r410" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r381" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r183" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r184" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r182", "r213" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r188" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r185", "r188", "r466" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r187" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r185", "r187", "r465" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r189" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r185", "r189", "r467" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r186" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r185", "r186", "r464" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r190", "r468" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r328", "r330" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r328", "r330", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Outstanding equity interests" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r356", "r357", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Paid to seller" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r355", "r358", "r360" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r25", "r87" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r87", "r89" ], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r392" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r190", "r320" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage Backed Securities [Member]", "terseLabel": "Mortgage-backed securities", "verboseLabel": "Mortgage-backed securities" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r231", "r232", "r233", "r234", "r509" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r99", "r100", "r378" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r14" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September\u00a030, 2021, and 59 million shares at December\u00a031, 2020" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r49", "r51", "r52", "r61", "r456", "r482" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r134", "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r305", "r306", "r316" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r320", "r327", "r503" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r65", "r444" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Medical care costs" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r63" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "negatedLabel": "Less: other operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r94", "r97", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r404", "r450", "r451", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r251", "r269", "r270", "r402", "r404", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r260", "r269", "r270", "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r32", "r252" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Percentage of contractual interest rate on notes", "verboseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33", "r94", "r97", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r404" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r33", "r94", "r97", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r296", "r299", "r300", "r301", "r401", "r402", "r404", "r405", "r470" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": { "auth_ref": [ "r213" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r196", "r216", "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Estimated Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r196", "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Total Number\u00a0of Positions" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "auth_ref": [ "r213" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Debt securities, available-for-sale", "verboseLabel": "Estimated Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Gross realized investment gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r195", "r215", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Available-for-sale investments" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "auth_ref": [ "r205", "r210", "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss", "terseLabel": "Debt securities held to maturity" } } }, "localname": "DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r26", "r403" ], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedTerseLabel": "Deferred debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r340", "r341" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r85", "r226" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r85", "r147" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r62", "r104", "r105", "r106", "r107", "r108", "r112", "r115", "r120", "r121", "r122", "r126", "r127", "r379", "r380", "r457", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share - Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r62", "r104", "r105", "r106", "r107", "r108", "r115", "r120", "r121", "r122", "r126", "r127", "r379", "r380", "r457", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net income per share - Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r54", "r55", "r56", "r99", "r100", "r101", "r103", "r109", "r111", "r129", "r204", "r295", "r302", "r334", "r335", "r336", "r347", "r348", "r378", "r393", "r394", "r395", "r396", "r397", "r398", "r496", "r497", "r498", "r535" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r260", "r269", "r270", "r388" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "verboseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r381", "r382", "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair value of assets measured on recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r381", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r260", "r269", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r382", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r260", "r269", "r270", "r381", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r260", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r260", "r320", "r321", "r326", "r327", "r382", "r415" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "(Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r260", "r269", "r270", "r320", "r321", "r326", "r327", "r382", "r416" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "(Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r260", "r269", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r382", "r417" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "(Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r260", "r269", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r406" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r193", "r194", "r200", "r201", "r202", "r206", "r207", "r208", "r209", "r212", "r215", "r217", "r218", "r219", "r268", "r293", "r377", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "negatedLabel": "Recognized loss" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r85", "r273", "r274" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt repayment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r220", "r221", "r410", "r448" ], "calculation": { "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r222", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r64", "r95", "r152", "r158", "r162", "r165", "r168", "r203", "r236", "r237", "r238", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r391" ], "calculation": { "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Total margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": { "auth_ref": [ "r192", "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five", "terseLabel": "Amortized Cost, Due one year through five years" } } }, "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": { "auth_ref": [ "r191", "r462" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Amortized Cost, Due in one year or less" } } }, "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r152", "r158", "r162", "r165", "r168", "r445", "r454", "r460", "r484" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income tax expense", "totalLabel": "Income before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r110", "r111", "r150", "r342", "r349", "r350", "r485" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r53", "r338", "r339", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r84", "r443" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in health care insurance liability balances during the period.", "label": "Increase (Decrease) in Health Care Insurance Liabilities", "terseLabel": "Medical claims and benefits payable" } } }, "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPremiumsReceivable": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in the premium receivable balance on the balance sheet.", "label": "Increase (Decrease) in Premiums Receivable", "negatedTerseLabel": "Reduction in premiums" } } }, "localname": "IncreaseDecreaseInPremiumsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r116", "r117", "r118", "r122" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r224", "r225" ], "calculation": { "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill, and intangible assets, net", "totalLabel": "Total" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendIncomeOperating": { "auth_ref": [ "r458" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.", "label": "Interest and Dividend Income, Operating", "terseLabel": "Other revenue" } } }, "localname": "InterestAndDividendIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r57", "r146", "r400", "r403", "r459" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Contractual maturities of investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r199", "r446", "r469", "r505", "r533" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r95", "r160", "r203", "r236", "r237", "r238", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r369", "r372", "r373", "r391", "r408", "r409" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r95", "r203", "r391", "r410", "r452", "r477" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31", "r95", "r203", "r236", "r237", "r238", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r369", "r372", "r373", "r391", "r408", "r409", "r410" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r381" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r487", "r490" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "periodEndLabel": "Medical claims and benefits payable, ending balance", "periodStartLabel": "Medical claims and benefits payable, beginning balance", "terseLabel": "Total", "verboseLabel": "Medical claims and benefits payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r489" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Current year" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r489" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Prior years" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r488" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "totalLabel": "Total medical care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "terseLabel": "Insurance Claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r12", "r451", "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Amount outstanding under letter of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Total" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r33", "r235" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r6", "r30" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Other operating" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r83", "r86" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r47", "r50", "r56", "r60", "r86", "r95", "r102", "r104", "r105", "r106", "r107", "r110", "r111", "r119", "r152", "r158", "r162", "r165", "r168", "r203", "r236", "r237", "r238", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r380", "r391", "r455", "r480" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r481" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "terseLabel": "Investment income" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Other expenses, net", "negatedTotalLabel": "Total other expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expenses, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r152", "r158", "r162", "r165", "r168" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r157", "r158", "r159", "r160", "r162", "r168" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r48", "r51", "r366", "r367", "r370" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net", "totalLabel": "Other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r40", "r43", "r198" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized investment (loss) income" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r41", "r44" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "terseLabel": "Less: effect of income taxes" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r66" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]", "terseLabel": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Contingent consideration liabilities settled" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r82", "r489" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total paid" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r71", "r74" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r77" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock purchases", "terseLabel": "Payments to settle shares purchased" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r72" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Net cash paid in business combinations", "terseLabel": "Net cash paid in business combinations" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r181" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, equipment and capitalized software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at fair value measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r279" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r279" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r410" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r453", "r479", "r486", "r502" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premium revenue" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r23", "r24" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r75" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from senior notes offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r75", "r94" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from borrowings under term loan facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r76", "r80" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r39", "r227", "r407" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, equipment, and capitalized software, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r15", "r22", "r410", "r478", "r504" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Receivables", "verboseLabel": "Total receivables" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r176", "r178", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r78", "r94" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayment of term loan facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReservesReportedToOtherAgenciesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.", "label": "Reserves Reported to Other Agencies [Table Text Block]", "terseLabel": "Amounts due to government agencies" } } }, "localname": "ReservesReportedToOtherAgenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r9", "r87", "r89", "r447", "r474" ], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "verboseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsNoncurrent": { "auth_ref": [ "r507", "r508" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Noncurrent", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r302", "r337", "r410", "r476", "r499", "r501" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r99", "r100", "r101", "r103", "r109", "r111", "r204", "r334", "r335", "r336", "r347", "r348", "r378", "r496", "r498" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r91", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Premium Revenue Recognition and Premiums Receivable" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r58", "r95", "r143", "r144", "r157", "r163", "r164", "r170", "r171", "r174", "r203", "r236", "r237", "r238", "r241", "r242", "r243", "r245", "r247", "r249", "r250", "r391", "r460" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenue", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of receivables" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r33", "r97", "r269", "r271", "r296", "r299", "r300", "r301", "r401", "r402", "r405", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Long term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of denominators for the computation of basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair value measurements of senior notes" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Schedule of liability for unpaid claims and claims adjustment expense" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r9", "r89", "r447", "r474" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r152", "r155", "r161", "r223" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r152", "r155", "r161", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Operating segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r92", "r130", "r131", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r288", "r293", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r140", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r157", "r158", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r174", "r229", "r230", "r492" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r152", "r156", "r162", "r166", "r167", "r168", "r169", "r170", "r173", "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Segments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtNarrativeDetails", "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Shares outstanding at the beginning of the period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r90", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r140", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r157", "r158", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r174", "r223", "r228", "r229", "r230", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r54", "r55", "r56", "r99", "r100", "r101", "r103", "r109", "r111", "r129", "r204", "r295", "r302", "r334", "r335", "r336", "r347", "r348", "r378", "r393", "r394", "r395", "r396", "r397", "r398", "r496", "r497", "r498", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r129", "r444" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r302", "r332", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Common stock authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r13", "r14", "r295", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Common stock purchases (in shares)", "terseLabel": "Repurchased of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r13", "r14", "r295", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Common stock purchases", "terseLabel": "Repurchased of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r19", "r20", "r95", "r177", "r203", "r391", "r410" ], "calculation": { "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r55", "r95", "r99", "r100", "r101", "r103", "r109", "r203", "r204", "r302", "r334", "r335", "r336", "r347", "r348", "r364", "r365", "r374", "r378", "r391", "r393", "r394", "r398", "r497", "r498", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r93", "r280", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r399", "r411" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r399", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r399", "r411" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r488" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current year" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r488" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "terseLabel": "Prior years", "verboseLabel": "Prior period claims, favorable development" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails", "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r193", "r194", "r200", "r201", "r202", "r268", "r293", "r377", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Average cost (USD per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Notes Securities [Member]", "terseLabel": "U.S. Treasury notes" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r132", "r133", "r135", "r136", "r137", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r114", "r122" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Denominator for diluted net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "negatedTerseLabel": "Stock purchases (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r112", "r122" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted-average number of shares issued:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeperShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267963-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1-5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r505": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r523": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r524": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r525": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r526": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r527": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r528": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r529": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r530": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r531": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r532": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r533": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r534": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" } }, "version": "2.1" } ZIP 67 0001179929-21-000171-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001179929-21-000171-xbrl.zip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ⅅ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end